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ABSTRACT

Objectives: The aims of this study were to: 1) Assess whether naturally induced anti-HPV
antibodies are associated with subsequent acquisition of genital HPV 6, 11, 16, and 18 infections
in men, 2) assess the recurrence (redetection) of genital HPV infections of the 9-valent vaccine
HPV types and investigate factors associated with recurrent infections among men, and 3) assess
the risk of type-specific sequential acquisition of anal HPV infection following a genital HPV
infection of the 9-valent vaccine HPV types among men who have sex with women (MSW).
Methods: 4,123 healthy men were followed every six months (median follow-up time 4.1 years).
HPV antibodies were measured at baseline using a virus-like particle-based ELISA assay.
Genital and anal HPV genotypes were detected using the Roche Linear Array assays. KaplanMeier curves and Cox models were developed to assess associations between serum anti-HPV
antibody and subsequent incident HPV infections. Individual type analyses and grouped analyses
were carried out to assess type-specific recurrence of the 9-valent vaccine HPV types. Risk of
sequential anal HPV infection was assessed by examining incident rate ratios (IRR) and adjusted
hazard ratios (aHR) among men with a prior genital HPV infection compared to men without a
prior genital HPV infection.
Results: 1) Significantly higher rates of incident infections were observed for HPV 16 among
baseline HPV 16 seropositive men (aHR 1.37, 95% CI 1.01-1.86). Risk of persistent HPV 18
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infection was significantly lower among HPV 18 seropositive men in unadjusted models, but not
in the adjusted model, while incident and six-month persistent HPV 6 and 11 infections did not
differ by baseline serostatus. 2) Up to 31% of prior prevalent and 20% of prior incident HPV
infections recurred over time in individual type analyses. New female sexual partners, frequency
of sexual intercourse with female partners, and new male sexual partners were associated with
type-specific recurrence of HPV infections (HPV 6, 16, 31 and 58). In grouped analyses, lifetime
number of male sexual partners (aOR = 2.40, 95% CI 1.19-4.84) and number of new male sexual
partners (aOR 2.35, 95% CI 1.16-4.74) were associated with recurrence of HPV infections. 3) In
individual type analyses, men with a prior HPV 16 genital infection had a significantly higher
risk of subsequent anal HPV 16 infection (aHR=4.63, 95% CI 1.41-15.23). Significantly higher
HRs were observed for any of the nine HPV types (aHR= 2.8, 95% CI1.32-5.99), high risk HPV
types (aHR=2.65, 95% CI 1.26, 5.55) and low risk HPV types (aHR=5.89, 95% CI1.29, 27.01) in
grouped analyses.
Conclusion: Baseline seropositive status among men was not associated with a reduction in
subsequent incident genital HPV 6, 11, and 16 infections, but with a possible protective effect for
persistent HPV 18 infections. Men are also susceptible to recurrence of type-specific genital
HPV infections, and recurrence of HPV infection was associated with high-risk sexual behaviors.
MSW men with prior genital HPV infections are more likely to have a subsequent type-specific
anal HPV infection than men who did not have prior genital HPV infections. Understanding the
natural history of HPV infections among men is essential to control HPV associated diseases in
both men and women.

vii

INTRODUCTION

Human papillomavirus (HPV) is one of the most common sexually transmitted infections
in men and women in the U.S. (1). HPV infection causes multiple cancers among men and
women, including cancers of the cervix, vagina, vulva, penis, oral cavity, head and neck, and
anal canal (2). The role of HPV in the etiology of cervical cancer has been well documented, and
vaccines targeting the most common HPV types (HPV 6, 11, 16 and 18) have been in use since
2006.3 Despite low uptake in the U.S., use of HPV vaccination has led to reduced prevalence of
HPV infections and premalignant conditions (3,4). Until recently, vaccination efforts have been
largely targeted toward girls and young women. The natural history of HPV infection among
men was not studied in detail until recently. It is now known that HPV infection in men plays an
important role in the etiology of penile, anal and oropharyngeal cancers. Furthermore, HPV has
been shown to be readily transmitted between sexual partners (5). Thus, an understanding of
HPV infection in men is critical for preventing HPV-related cancers among both men and
women.
In the proposed study, we plan to examine the association between serum anti-HPV
antibodies and subsequent incident infections for specific HPV types. The association between
anti-HPV antibodies and incident HPV infection has been studied among women, but similar
associations are not clearly understood among men. We will also assess recurrent HPV
infections, factors affecting recurrence for specific HPV types, and genital-anal genotype1

concordant HPV infections. For the proposed study, we will utilize data from the HPV Infection
in Men (HIM) Study. The HIM study is a natural history study of HPV in more than 4,000
healthy men recruited between 2005-2009 from the U.S., Brazil, and Mexico. Findings from the
proposed study will provide valuable information about the natural immune response to HPV,
recurrent HPV infections and genital-anal genotype-concordant HPV infections will be useful in
developing prevention strategies, such as HPV vaccination targeting men.
Background and significance
HPV is the most common sexually transmitted infection in the world and was responsible
for about 527,624 new cervical cancers that occurred worldwide in 2012 (6, 7). In the U.S.,
32,000 cancer cases in men and women were attributed to HPV in 2009, with the cost for
prevention and treatment of HPV associated diseases estimated to be $8 billion per year (7, 8).
An estimated 79 million people are currently infected with HPV, and 14 million individuals
acquire new HPV infections each year in the U.S. (9). More than 50% of sexually active
individuals are infected with one or more types of HPV at some point in their lives (10).
HPVs are a group of more than 150 related viruses, with about 40 distinct types that infect
the genital area (11). HPV infections can be broadly classified as mucosal (α genus) and
cutaneous, (including α, β, γ, μ (Mupa), and Nv (Nupa) genera) (12). Alpha (α ) HPV genus
(including HPV 6, 11, 16, 18, 31, 33, 45, 52, 58 etc) infections can lead to the development of
various cancers (cervix, vulva, vagina, penis, and oropharynx), as well as benign lesions such as
genital warts and respiratory papillomatosis (13, 14). HPV 16 and 18 are the most common
oncogenic (high-risk) types and account for about 70% of cervical cancers, 85% of anal cancers,
and 47% of penile cancers (15, 16). HPV 6 and 11 are the most common non-oncogenic (lowrisk) types and account for about 90% of genital warts (15). HPV DNA is detected in
2

approximately 88- 94% of anal cancers (24, 25), 29-82% of penile carcinoma cases (19, 20), 70100% of penile intraepithelial neoplasia (PeIN) (18), and 80-100% of genital warts (22, 23).
Among men, genital HPV prevalence has been reported to be as high as 73% (17). In 2007,
WHO (IARC) concluded that HPV 16 infection is a class 1A carcinogen for the development of
penile, anal and oropharyngeal cancers (14). According to 2007-2011 SEER data, incidence
rates for oropharyngeal, anal and penile cancers were 11.0 per 100,000, 1.8 per 100,000 and 1.0
per 100,000, respectively; with an increasing number of cases occurring due to HPV infection in
the U.S. (18).
Immunization with one of the approved HPV vaccines provides an important opportunity
for prevention of HPV infection and associated diseases in men and women. The three currently
available options include the bivalent (protecting against HPV 16 and 18), quadrivalent (HPV 6,
11, 16, and 18), and recently approved 9-valent (HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58)
vaccines (26, 27). Although only one-third of girls aged 13-17 years received all three
recommended doses of an HPV vaccine since the first HPV vaccine approval in 2006, the
prevalence of vaccine type HPVs has decreased by 56% among females in this age group,
highlighting the potential to eliminate the HPV types responsible for most HPV-related disease
should higher rates of vaccine dissemination be achieved (3). Furthermore, a recent study
observed a reduced prevalence of HPV 16/18 type in high grade cervical intraepithelial neoplasia
(CIN2/3) among vaccinated women (4).
Vaccination leads to a robust serum antibody response that is associated with protection
against future anogenital HPV infections and HPV-associated precancerous and cancerous
lesions (28). Virus-like particle (VLP)-based ELISA assays have been used to measure serum
HPV antibodies, which correlate well with protection against incident viral infection (29). HPV
3

antibodies are also produced following natural infection but at lower levels, particularly in men
(29-32). While these antibodies from natural infection are likely markers of moderate immunity
against subsequent infections and precancerous lesions among women (33- 35), the few studies
conducted to date do not indicate a protective effect among men (30-32). While studies have
examined recurrence (redetection) of HPV infection among women (36-39), to our knowledge
no previous study has examined the recurrence of HPV infections among men. Similarly only
few studies have examined the cervical and anal genotype-concordant HPV infections among
women (44-46). To the best of our knowledge, studies examining sequential acquisition of
genital and anal genotype-concordant infections, among men who have sex with women (MSW),
have not been conducted.
In the current study, we plan to evaluate the baseline serum antibody status for α-mucosal
HPV types (6, 11, 16, and 18) and their role in subsequent incidence and persistence of HPV
infection among men. We will also assess the concordance between genital and anal HPV
infections for 9- vaccine type HPVs (HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58) among MSWs.
Findings from this study will help shed light on natural immunity against HPV in men and
factors associated with persistence and recurrence of HPV infection. These results will be
helpful to promote the HPV vaccination and increase utilization among men as well as women.
Specific aims and objectives
The purpose of this study is to assess the incidence, persistence, and recurrence of genital
α-mucosal HPV infections (HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58) and evaluate whether HPV
antibody status is associated with the natural history of these infections. We plan to accomplish
these goals by pursuing the following specific aims:
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Aim 1: Examine the association between baseline serum α-mucosal anti-HPV antibodies
(HPV 6, 11, 16 and 18) and subsequent incidence and persistence of incidentally acquired
type-specific genital HPV infection among men aged 18-70 years in the HIM study cohort.
Objective 1.1 - Determine the incidence rates of genital HPV 6, 11, 16 and 18 infections among
baseline seronegative and seropositive subjects.
Hypothesis 1.1 - Our hypothesis is that incidence rates do not differ by baseline HPV serostatus.
Objective 1.2 - Determine the rate of persistence of incidentally acquired infections, with
duration of 6 months or more, for genital HPV 6, 11, 16 and 18 infections among baseline
seronegative and seropositive subjects.
Hypothesis 1.2 - Our hypothesis is that rates of persistent infections do not differ by baseline
HPV serostatus.
Aim 2: Estimate the rate of recurrent genital α-mucosal HPV infections (HPV 6, 11, 16, 18,
31, 33, 45, 52 and 58) among men aged 18-70 years, and the factors associated with recurrent
infections.
Objective 2.1 - Estimate the rate of recurrent genital HPV infections for α-mucosal HPV vaccine
types (HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58) among 4,123 men in the HIM study participants.
Hypothesis 2.1 - Our hypothesis is that the recurrence rates are lower than 10% for mucosal αHPVs.
Objective 2.2 – Investigate factors associated with recurrent infections among 4,123 men in the
HIM study for genital HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58.
Hypothesis 2.2 - Our hypothesis is that risk of recurrent infections will be higher among men
aged 18-30 years, those from Brazil, current smokers, men who consume alcohol more than two
drinks per day and those with riskier sexual behaviors (≥18 lifetime sexual partners, and ≥2
recent sexual partners).
Aim 3: Examine sequential genital and anal genotype-concordant HPV infections (HPV 6, 11,
16, 18, 31, 33, 45, 52 and 58) and identify factors associated with anal HPV infections
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following a prior genotype-concordant genital HPV infection among men who have sex with
women (MSW).
Objective 3.1 – Identify sequential genital and anal genotype-concordant HPV infections for
HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58.
Hypothesis 3.1 - Our hypothesis is that anal HPV infections are more likely to occur among
MSW men who had a prior genotype-concordant (same genotype) genital HPV infection
compared to men with no-prior genital infection.
Objective 3.2 - Investigate factors associated with an incident anal HPV infection following a
prior genotype-concordant genital HPV infection, for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and
58.
Hypothesis 3.2 - Our hypothesis is that anal HPV infection following genital HPV infection
occurs due to auto-inoculation and therefore is not associated with sex with female partners
among MSW.
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REVIEW OF LITERATURE

Human papillomavirus (HPV)
World statistics:
Worldwide prevalence of HPV among women without cervical abnormalities is 11.7%,
with the most prevalent genotypes being HPV 16 (3.2%) and HPV 18 (1.4%) (5). Higher
prevalence has been observed in sub-Sahara Africa (24%), Eastern Europe (21%) and Latin
America (16%). The prevalence increases sharply among women with cervical pathology,
reaching approximately 90% in grade 3 intraepithelial neoplasia (5). Among men, HPV
prevalence ranging from 1.3%-72.9% has been documented in various studies (14).
Cervical cancer is the second most common cancer among women aged 15-44 years, with
approximately 528,000 new cervical cancers cases and 266,000 deaths occurring annually in the
world (47). Almost all cervical cancers are caused by HPV infection, with HPV 16 and 18
responsible for 70% of these cancers (11). Apart from cervical cancers, HPV also causes anal,
vulvar, vaginal, penile, and oropharyngeal cancers. According to a WHO 2013 publication,
worldwide numbers of new cases for HPV-related cancers were as follows: 27,000 anal cancers,
27,000 vulvar cancers 13,000 vaginal cancers, and 26,000 penile cancers (21, 47). Penile cancer
is more common in some parts of Asia, Africa and South America, and accounts for up to 10%
of cancer cases among men (47). Worldwide annual age-adjusted incidence and mortality rates
7

for oropharyngeal cancer (OPC) are 5.9 and 3.3 per 100,000 persons, respectively (47). In
developed countries, HPV associated OPC incidence rates are increasing among men and HPV
16 type has been implicated in most cases (48, 49).
U.S. statistics:
Each year 26,000 new cancer cases (17,000 in women and 9,000 in men) are attributable to
HPV in the U.S. (50). Cervical cancer is the fourth most common cancer among women aged
15-44 years in the U.S., and about 3.9% women in the general population have HPV 16/18
infection at any given time (51). Annual incidence and mortality rates for cervical cancer are 7.8
and 2.3 per 100,000 women based on SEER 2007-2011 data (15), resulting in approximately
13,000 new cervical cancer cases and 6,600 cervical cancer deaths each year (51). For vulvar
cancers, incidence and mortality rates are 2.4 and 0.5 per 100,000 women, respectively (15).
Anal cancers are also associated with HPV infection with annual incidence and mortality rates of
1.8 and 0.2 per 100,000 in men and women (15). Penile cancers are rare in the U.S. and they
account for less than 1% of cancers diagnosed among men (15). Oropharyngeal cancer (OPC)
annual incidence in the U.S. is 10.6 cases per 100,000 persons, with an annual mortality rate of
2.5 per 100,000 persons (15). OPC incidence rates are about 4 times higher in men compared to
women (52). Approximately 45,780 new cases and 8,650 deaths were attributed to OPC in the
US in 2014 (53).
HPV classification
HPV is a non-enveloped double-stranded DNA virus that primarily infects stratified
epithelia (54). HPV infections can be classified as mucosal (genus) and cutaneous, which
include α, β, γ, μ (Mupa), and Nv (Nupa) genera (55). These genera differ according to the
8

primary site of infection (Table 1) (56-58). The α-HPV genus includes the most important HPV
types associated with cervical, vulvar, vaginal, penile, anal, and oropharyngeal cancers and
genital warts; including HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 (56). Alpha HPV genotypes
can be further classified as high-risk (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 68, 69, and
82) or low-risk (HPV 6, 11, 40, 42, 43, 44, 54, 61, 72, and 81), based on their oncogenicity (57).
Most HPV infections (about 90%) are asymptomatic and resolve within two years, but persistent
HPV infections can cause a variety of cancers and benign diseases (59).
Table 1: Different genera of papillomavirus family with HPV types and type of tissues
affected (58)
Genus

HPV type

Tissue
tropism

Alpha
6, 11, 16, 18, 26, 30, 31, 33, 34, 35, 39, 40, 42, 43,
papillomavirus 44, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 64,
66, 67, 68, 69, 70, 71, 72, 73, 74, 81, 83, 84, 85,
86, 87, 89, and 90

Mucosal

7, 40, 43 and c91
2, 3, 10, 27, 38, 29, 57, 77, 78 and 94

Beta
papillomavirus
Gamma
papillomavirus
Muppa
papillomavirus
Nupa
papillomavirus

5, 8, 9, 12, 14, 15, 17, 19, 20, 21, 22, 23, 24, 25,
36, 37, 38, 47, 49, 75, 76, 80, 92, 93 and 96
4, 48, 50, 60, 65, 88 and 95

Mucosal and
cutaneous
Cutaneous
Cutaneous
Cutaneous

1 and 63

Cutaneous

41

Cutaneous

Source: Reproduced from the publication by Koning et al (2008)58.
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Mechanism of infection
HPVs infect keratinocytes in the basal cell layer of the stratified epithelium, which is the
only tissue in which they can replicate (60). HPVs replicate in the nucleus of keratinocytes in a
differentiation-dependent manner, meaning that viral gene replication and transcription are
tightly controlled by keratinocyte differentiation (60). Expression of HPV viral genes leads to
expression of six nonstructural viral regulatory proteins (E1, E2, E4, E5, E6 and E7) and two
structural viral capsid proteins (L1 and L2) (61). The E6 and E7 viral proteins are oncogenes,
leading to deactivation of p53 and pRb tumor suppressor proteins (61). Various HPV protein
encoding genes and organization of the HPV genome are shown in Figure 1 (62).

Figure 1: Genomic organization of high-risk mucosal HPV virus (62)
Source: Used with permission of Dr. Anna Giuliano, from the HIM Study presentation materials.
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As shown in the figure, the HPV viral genome contains early (E) regions and late (L)
regions, which indicate the position of the gene and their timing of expression in the viral life
cycle (61, 62). E1 and E2 proteins help with viral replication and transcription, while E4 helps
with viral release. E6 and E7 are major transforming proteins of the oncogenic HPVs and also
have roles in the normal viral cell cycle (62). E5 protein has a role in growth stimulation and
immune evasion (61, 62). Among the late region proteins, L1 is a major capsid protein and L2 is
a minor capsid protein. The L1 major capsid protein binds with the basement membrane heparan
sulfate proteoglycans (HSPGs), which are exposed due to any previous trauma to the skin (60).
Gene replication and transcription are controlled by the upstream regulatory region (URR),
which also contains promoter and enhancer regions (60-62).
The cell-mediated immune (CMI) response is responsible for clearing HPV-associated
infection and benign lesions and is accompanied by a CD4+ T cell-dominated response (62).
Failure of an effective CMI response, followed by high-risk HPV infection, can lead to persistent
infection and increased probability of high grade intraepithelial neoplasia and invasive
carcinoma (62). HPV infection effectively evades innate immune recognition, due to the fact
that HPV is exclusively an intra-cellular infection; there is an absence of viremia, virus-induced
cell death, and replication-associated inflammation (62). HPV also downregulates innate
immune signals; which leads to inhibition of type I interferons (IFN-α and IFN-β), lack of
signals for Langerhans cell activation/migration, and lack of recruitment of stromal dendritic and
macrophage cells (62). Evasion of these immune responses allows infections to persist for
months to several years and it may lead to high-grade intraepithelial neoplasia and upregulation
of E6 and E7 proteins, which further suppresses the immune response (62). After HPV infection,
non-dividing epithelial cells retain a normal active cell cycle, which may result in thickened,
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exophytic lesions (60). Virus is released as the epithelial cells exfoliate. In cells that do not
senesce, the viral genome integrates into the host chromosome which is associated with
neoplastic progression (60).
As indicated previously, HPV infection and lesions are primarily targeted by CMI (60-62),
with antibody response (humoral response) shown to follow the CMI response (62). Unlike the
antibody response following infection with other viruses, lower antibody levels are detected in
both animals and humans, which may be due to HPV’s ability to evade the innate immune
recognition (61, 62). As viral particles are released at the surface of the epithelium (rather than
in blood or lymph nodes) as cell exfoliates and there is no viremia, circulating immune cells are
not exposed to HPV. The humoral response is initiated in lymph nodes and this may be one of
the explanations for lower antibody levels (62). Furthermore, current methods for serum
antibody measurement may not be sensitive enough to detect low antibody levels and this may
explain different findings observed in previous studies (31, 62).
HPV vaccines
Three HPV vaccines are currently approved for use in the U.S. A quadrivalent vaccine
(Gardasil, HPV 6, 11, 16, 18) approved in 2006 (63,64), a bivalent vaccine (Cervarix; HPV 6 and
11) approved in 2009 (65), and a nonavalent vaccine (Gardasil 9, HPV 6, 11, 16, 18, 31, 33, 45,
52, 58) approved in 2014 (66). Among the types covered by these vaccines, HPV 16 and 18 are
responsible for about 64% of invasive cancers, 70% of cervical cancers; while HPV 6 and 11
cause 90% of genital warts and most cases of recurrent respiratory pappilomatosis (63, 66).
These vaccines include virus-like particles (VLPs), which are prepared from the recombinant L1
capsid protein of HPV, and are therefore not live vaccines (63). HPV vaccine is recommended
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starting at age 11-12 years for routine vaccination (67). The Advisory Committee on
Immunization Practices (ACIP) of the CDC also recommends vaccination for 13-26 year old
females and 13-21 year old males not vaccinated previously (66). These recommendations are
extended to include men up to 26 years of age who are considered to be at higher risk of HPV
acquisition (men who have sex with men or who are immune-compromised) (66).
In December 2014 a 9-valent vaccine (Gardasil-9) covering 5 additional HPV types (31,
33, 45, 52 and 58), along with quadrivalent HPV types (HPV 6, 11, 16 and 18) was approved in
US (66). The 5 additional HPV strains are responsible for about 10% of HPV associated cancers
and about 15% of cervical cancers (66). In a phase III clinical trial, the 9-valent vaccine
demonstrated 96.7% efficacy in the prevention of cervical intraepithelial neoplasia grade 2,
vulvar intraepithelial neoplasia grade 2 or 3, and vaginal intraepithelial neoplasia grade 2 or 3
caused by HPV 31, 33, 45, 52, or 58 (66).
According to a 2014 report, vaccine coverage for HPV among adolescent girls in the U.S.
was 57.3% for one or more doses and 37.6% for all three doses (68). Coverage among
adolescent boys was much lower, with 34.6% coverage for one or more doses and 13.9% for all
three doses (68). HPV vaccination coverage among adolescents has not increased in recent
years, and the coverage rates are far below the Healthy People 2020 target of 80% coverage for
both adolescent girls and boys (68). Australia was the first country to launch a governmentsponsored HPV vaccination program, and between 2007-2009, approximately 83% girls aged
12-17 years received at least one dose of the quadrivalent HPV vaccine, and 70% completed all
three-dose series (69). Four years after initiation of this vaccination program, there was a
significant reduction in the prevalence of vaccine-type HPVs (6, 11, 16, and 18) (69).
Reductions in HPV-associated diseases and pre-malignant lesions in vaccinated populations have
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also been documented in Australia, Denmark, and the U.K. (70-72). Thus, increased efforts to
expand HPV vaccination coverage are required to prevent HPV- associated diseases in the U.S.
HPV infection among men
Although HPV natural history studies originally focused exclusively on women, the
importance of HPV etiology and diseases among men has increasingly been recognized and
studied. One such study, the HPV Infection in Men (HIM) Study is a prospective natural history
study conducted among healthy men from three different countries (U.S., Brazil, and Mexico)
(2). The HIM Study was the first large study to report the prevalence and type distribution of
HPV among men residing in the USA, Brazil and Mexico (2). The initial findings of the HIM
Study reported an overall HPV prevalence of 65.2%, with the highest prevalence in Brazil
(72.3%), followed by Mexico (61.9%) and the U.S. (61.3%) (2). A systematic review in 2006
detected HPV prevalence ranging from 1.3%-72.9% among men, with more than 56% studies
reporting prevalence over 20 % (14) with HPV 16 being the most commonly detected type. Five
cross-sectional studies described young age at first sexual intercourse, greater number of lifetime
and recent sexual partners, and high frequency of intercourse as risk factors for HPV infection in
men (73-76). The HIM study reported an incidence rate of 38.4 per 1,000 person month (95% CI
34.3-43.0) for new genital HPV infections (8). For oncogenic HPV infections, this study
reported hazards ratio (HR) of 2.40 (95% CI 1.38-4.18) for at least 50 partners vs. not more than
one partner and HR of 2.57 (95% CI 1.46-4.49) for at least three male partners vs. no recent
partners (8). Average duration of an HPV infection was 7.5 months and for HPV 16 was 12.2
months (8). Earlier cross-sectional and longitudinal studies also indicated that circumcision and
condom use were associated with reduced risk of HPV infection among men (14, 73-78). The
HIM study also showed that men have a consistent risk of HPV across the lifespan (ages 18-70
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years) (13, 81). Oncogenic HPV detection was independently associated with lifetime and recent
number of sexual partners, while non-oncogenic HPV infection was associated with only lifetime
number of sexual partners (82). A few studies have found that smoking is a possible risk factor,
while others found no association (83-85).
Previous literature
HPV antibodies and incident infection
Among women
Various studies among women have assessed the effect of anti-HPV antibodies on
subsequent risk of incident infection acquisition. High levels of HPV 16 IgG antibodies were
shown to be associated with reduced incidence of subsequent infection with HPV16 and related
types (31, 33, 35, 52, and 58) (86). Persistent antibodies to HPV 16 (p =0.02), HPV31
(p<0.001), HPV33 (p=0.03), HPV35 (p=0.002), HPV52 (p=0.007), HPV45 (p=0.003), and
HPV53 (p=0.01) were also found to be associated with reduced risk of HPV incidence (87).
Further studies also have shown protection against HPV infection among seropositive
individuals (33-35, 88, 89). Although three studies did not find any association between antiHPV antibodies and subsequent protection against incident type-specific HPV infection (90-92),
the majority of studies indicated a moderate protective effect of anti-HPV antibodies against
subsequent infections among women. Various studies have indicated a higher seroprevalence of
anti-HPV antibodies among women compared with men for both oncogenic and non-oncogenic
HPV types (93-97). Factors including differential immune response, serum antibody cut-off
levels, differences in assay techniques, and different durations of antibody levels have been
suggested for the difference in antibody response observed among women in these studies.
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Among men
Only three studies have previously assessed the association between HPV antibodies and
subsequent incident infection in men (29-31). A study conducted in HPV Infection in Men study
cohort Tucson-Arizona, did not show a protective effect for HPV 16 and 18 antibodies (29), but
this study had limited follow-up time, sample size, and availability of quantitative assessments
for serum antibody levels. A study based on 2,187 HIM Study participants (from USA, Brazil
and Mexico) also did not show an association between serum antibodies and reduction in
subsequent infection for HPV 16 (30), although this study did not include all HIM Study
participants or data for HPV genotypes 6, 11, and 18. A recent study among HIV-negative and
HIV-positive men did not show protective effects against subsequent infection but the study only
included MSM (men who have sex with men) subjects (31). Thus, previous studies do not
provide sufficient evidence regarding the association between anti-HPV antibodies and
subsequent HPV infection among all men.
Differences between men and women’s antibody response to HPV infection may be due to
differential sex-related immune responses, differences in assay techniques, and varying duration
of serum antibody presence (30). Various studies have reported sex differences for HPV
seroprevalence, with women having higher seroprevalance compared to men (93-98). HPV
infection of keratinized epithelium among men may be less likely to induce an immune response,
and as a result lower levels of antibodies, compared to larger mucosal surface area among
women (30). Difference in assay techniques can also be a possible explanation. For example,
VLP-based direct-binding ELISA assay that measures total type-specific binding IgG antibodies
may yield different results compared competitive neutralization assay that binds only
neutralizing epitopes in HPV viral capsid (28, 30). Assessment techniques and cut-off levels of
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serum antibodies can also affect the observed association. For example, use of only high
antibodies for 2 or more visits may yield different results compared to assessment of serostatus
only at baseline (86, 91, 92).
Recurrent HPV infections
Among women
Few studies have examined recurrent infection or redetection of HPV infection after
clearance among women. Reinfection was associated with new sexual partners, including among
older women (38). Winer et al. reported that redetection of 19.4% incident infections occurred
within a year (36). A study by Rodriguez et al. assessed type-specific recurrence of carcinogenic
HPV types and development of subsequent cervical intraepithelial neoplasia (99). They found
that 7.7% of HPV-infected women had intervening negative results, while 2.7% had definite
clearance (≥ 2 intervening negative results) followed by re-appearance (99). Moscicki et al.
reported that 18.1% of HPV 16 infections were redetected among women who cleared an HPV
16 infection, and factors associated with risk for redetection included douching, current use of
medroxyprogesterone, reporting more than one sex partner or having a new sex partner, and
having a sexually transmitted infection (100).
To our knowledge, no previous study has examined the recurrence (redetection) of HPV
infection after clearance of initial incident infection among men.
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Concordant genital and anal HPV infections
Among women
Only a few studies have assessed concurrent genital-anal infection or sequential HPV
infection starting with a genital infection followed by an anal HPV infection with the same
genotype among women. Hernandez et al. assessed 1,363 women with paired anal and genital
samples in a cohort of adult women in Hawaii (44). According to their results, risk of concurrent
anal infection was 3-fold higher among women with cervical HPV infection as compared with
women of the same age and from the same population without cervical HPV infection. They
also reported a higher (26% identical and 53% partly identical) genotype-specific concordance
among concurrent anal and cervical infection, possibly due to a common source of infection (44).
Goodman et al. examined the genotype-concordant cervical HPV infection and subsequent anal
HPV infection among 751 women in this Hawaii HPV cohort (45). They reported a Relative
Risk (RR) of 20.5 (95% CI, 16.3-25.7) for acquiring a secondary anal infection after a primary
cervical infection with the same HPV genotype (45). Goodman et al. also showed similar results
with Hazards Ratios (HR) of 17.33 (95% CI 10.22-29.39) for any HPV type, HR of 17.95 (95%
CI, 9.34–34.52) for high risk HPV and HR of 16.24 (95% CI, 6.57–40.16) for low risk HPV
types (46). A cross-sectional study of 211 adult women in American Samoa by Hernandez et al,
2012 reported that 4% of women had concurrent cervical and anal HPV (101). They also found
that having a cervical HPV infection was associated with anal HPV with an age-adjusted OR
3.32, 95% CI (1.10-10.00) (101). Guler et al, 2013 evaluated the prevalence of coexisting anal
HPV infection and concordance of HPV types in women with cervical HPV infection (102).
They reported a high prevalence (52%) of coexisting cervical and anal infections, with 20% total
concordance and 58% partial concordance between the two sites (102).
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To the best of our knowledge, similar associations for genotype-concordant genital and
anal infection have not been examined among men. Our study will utilize the data from
participants of the HIM study cohort, who agreed to provide anal samples for the study (2,103,
104). Factors associated with incidence and persistence of anal HPV infection in this cohort has
been described previously (103, 104). Briefly, HPV anal HPV prevalence was 12.2% among
MSW and 47.2 % among MSM subjects (103). More than 10 lifetime female sex partners and a
primary sexual relationship of <1 year in duration were independently associated with anal HPV
detection among MSW subjects (103). Young age, more than two male anal sex partners in the
past three months, and never using a condom for anal sex in the past six months were associated
with detection of any anal HPV among MSM subjects (103). The incidence rate of anal HPV 16
and 18 among MSW subjects were 0.7 and 0.9 per 1000 person-months, respectively (104).
Among MSM subjects, incidence rates for HPV 16 and 18 were 4.8 and 3.8 per 1000 personmonths, respectively (104). Among MSM 5.1% subjects had a persistent HPV 16 infection,
while 0.6% MSW subjects had persistent infection for any genotype (104). Cigarette smoking
was associated with persistent infection of any genotype among both MSM and MSW subjects
(104). We will use data for MSW subjects for the analysis and examine the genotype-concordant
genital and anal infection among men.
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Introduction:
Genital HPV prevalence among men exceeds 70% in some regions of the world (105),
with HPV DNA detected in 29-82% of penile cancers (106, 107) and 80-100% of genital warts
(108, 109). Furthermore, nearly 10,000 new cases of HPV-related oropharyngeal cancers among
men are diagnosed in the U.S. each year (110). Although the antibodies produced following HPV
vaccination among men provides protection against future ano-genital HPV infections and
related diseases (111), it is unclear whether the antibodies produced after natural HPV infection
are sufficient to protect against subsequent infection in men.
Among women, antibodies produced in response to natural HPV infection are markers of
past infections and have been shown to provide partial immunity against subsequent infections
and precancerous lesions (112-114); however, not all studies observed these protective effects
(115-117). Differences in study findings may be due to the use of different antibody assays,
serum antibody levels, and time since first exposure to HPV (118). A prospective study of HPV
infection among men in Arizona did not show protective effects of circulating HPV antibodies
(119). However, this study was limited by a short follow-up time, small sample size, and lack of
a quantitative serum antibody assessment. An initial study of 2,187 participants in the
multinational HPV Infection in Men (HIM) Study also did not show an association between
serum antibodies and reduction in subsequent HPV 16 infections (118). However, this study was
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limited to only one HPV type with a median duration of two years follow-up. A recent study
among HIV-negative and HIV-positive men also did not show protective effects against
subsequent HPV infection for multiple HPV types, but the study was restricted to men who have
sex with men (MSM) (120).
In the current study, we provide the first comprehensive evaluation of incident genital
HPV 6, 11, 16, 18 (any duration infection and six-month persistent infections) by baseline
antibody status among the entire HIM Study cohort (n=4,123) followed for a median of 4.1
years.
Methods:
Study population
The HIM Study is an ongoing multinational study of the natural history of HPV among
men in Tampa, Florida (U.S.), São Paulo (Brazil), and Cuernavaca (Mexico). Details of this
study have been described previously (121). Briefly, healthy men were enrolled at each study site
and followed for a median follow-up of 4.1 years, with an average interval of 6.9 months
between visits. Men were eligible for the study if they: a) were 18–70 years of age; b) were
residents of one of the study sites; c) had no previous diagnosis of penile or anal cancers; d) had
never been diagnosed with genital or anal warts; e) had no symptoms of a sexually transmitted
infection (STI) and were not receiving treatment for an STI; f) were not participating in an HPV
vaccine study; g) had no history of HIV or AIDS; h) had no history of imprisonment,
homelessness, or drug treatment during the past six months; and i) were willing to comply with
10 scheduled visits every six months for four years with no plans to relocate during that time.
Subjects who reported never being sexually active and subjects who received HPV vaccines
were excluded.
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To increase access to men across a broad range of ages, sexual behaviors, and HPV risk,
participants were recruited from the general population, universities, and organized healthcare
systems. In Brazil, men were recruited from a facility for urogenital care (Centro de Referencia e
Tratamento de Doencas Sexualmente Transmissiveis e AIDS) and through general media
advertising. Men with non-sexually transmitted infections and related conditions (e.g. kidney
stones, hydronephorsis, and hypertrophied bladder) were included in the study. Furthermore,
partners and spouses of participants in a large cohort study of the natural history of HPV and
cervical neoplasia in women conducted in São Paulo were recruited for the HIM Study.
Employees and beneficiaries of the Instituto Mexicano de Seguro Social, factory employees, and
permanently assigned officials of the Mexican army were recruited at the Cuernavaca, Mexico
site. In the U.S., men were recruited from the University of South Florida and the greater Tampa
Bay area. Flyers were distributed, and monthly educational presentations were carried out to
promote the study and increase recruitment. Furthermore, mailed brochures and flyers and
advertisements in local and university papers were used to recruit subjects.
All eligible participants signed an informed consent, and approval was obtained from the
human subjects committees of the University of South Florida (Tampa, FL), Ludwig Institute for
Cancer Research (São Paulo, Brazil), Centro de Referencia e Treinamento em Doencas
Sexualmente Transmissíveis e AIDS (São Paulo, Brazil), and Instituto Nacional de Salud Publica
de Mexico (Cuernavaca, Mexico). A total of 4,123 HIM Study participants were eligible for this
study.
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Computer assisted self-interviewing (CASI)
Each participant completed an extensive self-administered demographic and behavioral
questionnaire assessing country of residence, age, race, ethnicity, marital status, education,
smoking status, alcohol consumption, and a detailed sexual behavior history. The questionnaire
was completed at baseline and at each six month follow-up visit. The questionnaire required
approximately 20 minutes to complete and was administered using computer-assisted selfinterviewing (CASI). The CASI method has been shown to be superior in reliability and
consistency compared to the paper-based questionnaire method (p <0.05) and is reported to be
user friendly, even for computer-inexperienced subjects (122). Furthermore, the CASI method
reduces errors due to faulty execution of skip instructions or confusing skip patterns and
encourages more complete reporting of sensitive behaviors, such as sexual behavior history (122,
123). Other advantages of CASI include low cost, (as interviewers are not required, and there is
no need to enter data into the computer separately), lower refusal rates for sensitive topics, and
ease of use in multisite trials (122, 124, 125).
Baseline serum antibody testing
A 10 milliliter venous blood sample was collected at baseline to measure serum antibodies
against four HPV genotypes (HPV 6, 11, 16, and 18). Serum anti-HPV antibody assessments for
HPV genotypes (6, 11, 16, and 18) were carried out using a virus-like particle (VLP)-based
enzyme-linked immunosorbent assay (ELISA) (126). Details of this assay have been described
previously (127). Briefly, insect cells from recombinant baculoviruses expressing HPV L1
capsid proteins were used to produce HPV VLPs. Absorbance values in optical density (OD)
were measured to assess seroreactivity. Serum samples from children (1-10 years old) were used
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as a negative control. The cut-off point for seropositivity for each HPV genotype was selected as
five SD above the mean absorbance value among the children. Positive and negative laboratory
serum controls were used in each assay run for quality control purposes. Laboratory staff was
blinded to participants’ HPV DNA status.
External genital HPV DNA samples
Three prewetted Dacron swabs were used to collect genital cell specimens from the
coronal sulcus/glans penis, penile shaft, and scrotum and were later combined to form a single
sample (121, 128). All specimens were stored at -80°C until genotyping was conducted. The
QIAamp DNA Blood Mini Kit (QIAGEN) was used to extract DNA from genital cell specimens.
Roche Linear Array kits were used for PCR and HPV DNA genotyping to detect 37 different
types of HPV (129). The presence of human β-globin was used to assess specimen adequacy
with an overall β-globin positivity of >98%.
Statistical analysis
Demographic characteristics were compared between seronegative and seropositive men at
baseline using Chi-square tests with Monte Carlo estimation of exact p-values. Only men who
were DNA-negative for the respective HPV type at the baseline visit were included in analyses.
Separate analyses were carried out for each of the four HPV genotypes (HPV 6, 11, 16 and 18)
by duration of infection (any duration for incident infections and >6 months duration for
persistent infection).
Incidence proportions (all incident HPV 6, 11, 16, and 18 infections regardless of duration)
and six-month persistent incidence proportions were calculated at each six-month interval among
subjects who had one or more follow-up visits after baseline. Follow-up times were calculated
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based on visit dates and participants who were late for their visit were included in the appropriate
time interval for the analysis. To estimate incidence proportions, the first detection of HPV DNA
at a follow-up visit was defined as an incident HPV infection (numerator). The number of
subjects who tested negative for HPV DNA at the beginning of each study interval was defined
as the at-risk population (denominator). For six-month persistent infections, a persistent infection
was defined as HPV DNA detection at two or more consecutive visits. Persistent infections also
included subjects with an intervening negative result (n= 20 for HPV 6, n=5 for HPV 11, n=22
for HPV 16 and n= 11 for HPV 18). Participants who were DNA- negative for the given HPV
type (at risk of acquiring a new infection) at the beginning of each study interval were defined as
at-risk subjects for six-month persistent infection.
Kaplan-Meier (KM) curves were constructed for incident and six-month persistent
infections for each of the four HPV genotypes (6, 11, 16 and 18). Cumulative incidence for each
genotype was compared between seropositive and seronegative subjects, with the log-rank test
used to determine significant differences by serum antibody status. Cox proportional hazard
models were used to calculate crude and adjusted hazard ratios (aHR) and 95% confidence
intervals (CI). A list of candidate variables was created based on descriptive analyses, previous
literature, and assessment of confounding by each variable. Variables were evaluated in both
backward and forward stepwise models. Final models included variables based on best-fit
approach based on the lowest Akaike information criterion (AIC) values. As sexual behavior
prior to acquisition of incident infections strongly influences HPV acquisition, we included the
following sexual behavior variables as time-varying covariates in final adjusted Cox models:
lifetime number of female sexual partners, number of new female sexual partners in the past 6-12
months, frequency of sexual intercourse with female partners in the past 6-12 months, lifetime
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number of male sexual partners, and number of new male sexual partners in the past 6-12
months. Due to the differences in HPV seroprevalence by sexual orientation, stratified analyses
were also conducted. To evaluate whether antibody levels were associated with subsequent
detection of incident infections, we categorized serum antibody levels into the highest tertile and
lowest two tertiles and compared these two groups to seronegative men (113, 120).
Results:
Serum antibody and HPV genotyping data were available for 4,103 subjects at baseline.
We excluded 250 (HPV 6), 55 (HPV 11), 311(HPV 16) and 90 (HPV 18) subjects who were
DNA-positive at the baseline visit for the respective HPV type. Therefore, baseline
seroprevalence analyses included 3,851 (HPV 6), 4,046 (HPV 11), 3,790 (HPV 16), and 4,011
(HPV 18) subjects who were DNA-negative for the specific HPV genotype.
Overall, baseline HPV6, 11, 16, and 18 seroprevalence was 8.1%, 13.9%, 12.4%, and
10.8%, respectively. Significant differences were observed between seropositive and
seronegative men for various covariates (Table 2.1). Seroprevalence increased with increasing
age, with the highest seroprevalence for HPV 6 (9.4%), 11 (16.2%), and 16 (16.4%) observed
among men ages 31-44, and the highest HPV 18 seroprevalence (17.9%) among men ages 45-73.
Brazil had the highest seroprevalence for HPV 6 (10.8%), 16 (16.9%), and 18 (13.0%), while
Mexico had the highest seroprevalence for HPV 11 (18.8%). Men who have sex with men
(MSM) had the highest seroprevalence for all four genotypes (HPV 6: 23.2%, HPV 11: 27.6%,
HPV 16: 28.6%, and HPV 18: 29.3%). Seroprevalence was highest among men reporting ≥10
lifetime male sexual partners (30.0%, 37.8%, 39.0%, and 40.4% for HPV 6, 11, 16, and 18
respectively).
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For HPV 6, 11, 16, and 18, the total numbers of incident infections were 319 (10.3%), 111
(3.5%), 362 (12.4%), and 200 (6.2%) among seronegative men, and 30 (10.6%), 17 (3.3%), 70
(16.7%), and 22 (5.6%) among seropositive individuals, respectively. Cumulative incidence
among seropositive individuals was higher after 18 months for HPV 16 (p-value= 0.007, Figure
2.1a, table 2.2a). For HPV 11 and 18, incidence proportions were generally lower among
seropositive individuals until the 13-18 month interval, followed by similar proportions (HPV 11
and 18) after 24 months. KM curves indicated a similar pattern with overall non-significant pvalues (p = 0.76 for HPV 11 and p = 0.69 for HPV 18) for the association between serostatus and
HPV acquisition. For HPV 6, cumulative incidences among seropositive and seronegative
subjects was similar (p-value= 0.728).
The total numbers of incident six-month persistent infections were 100 (3.5%), 37 (1.3%),
120 (4.5%), and 74 (2.5%) among seronegative men and 7 (2.8%), 2 (0.4%), 21 (5.5%), and 2
(0.6%) among seropositive individuals for HPV 6, 11, 16 and 18, respectively. Six month
persistent HPV 16 infections did not differ significantly between seronegative and seropositive
individuals (Figure 2.1b, Table 2.2b). The overall number of six-month persistent HPV 11 and
18 infections observed was low (two infections for each type over 4.1 year follow-up period).
Six-month persistent infections were not observed prior to month 31 among HPV 11seropositive
individuals and prior to month 19 for HPV18 seropositive individuals. Significantly lower
incidence of six-month persistent HPV 18 infections was observed among seropositive
individuals (p=0.02).
Risk of an incident HPV 16 infection was significantly higher among seropositive
compared to seronegative men (aHR 1.37, 95% CI 1.01, 1.86) (Table 2.3). A similar nonsignificant pattern was observed for risk of six-month persistent HPV 16 infections (aHR 1.26,
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95% CI 0.79, 2.01). Serostatus was not associated with risk of HPV 6, 11, and 18 incident
infections. However, risk of persistent HPV 18 infection was significantly lower among
seropositive men in unadjusted analyses (crude HR 0.22, 95% CI 0.06-0.91), but failed to reach
significance in the adjusted model (aHR 0.19, 95% CI 0.03, 1.37). In separate analyses adjusting
for demographic and sexual behavior variables one at a time, similar results to those shown in
Table 3.3 were observed (Appendix Table 2.1).
Table 3.4 shows the risk of incident and six-month persistent HPV 16 and 18 infections
by serostatus and sexual orientation. No significant associations were observed likely due to the
relatively small sample sizes in each stratum. No evidence of effect modification was observed
for HPV 18. However, serostatus was non-significantly associated with a decreased risk among
MSM and increased risk among heterosexual men. Similarly, no significant associations were
observed for HPV 6 and 11 (Appendix Table 2.2). In analyses by serum antibody levels, high
levels (highest tertile) of antibody were not significantly associated with reduced risk of
subsequent genital HPV infection (Appendix Table 2.3). In analyses comparing the lower two
tertile groups to the seronegative group, the incidence rate ratio for HPV 16 was 1.40 (945% CI,
1.01-1.89) and for persistent HPV 18 was 0.16 (95% CI 0.004-0.93).These results are
comparable to the results discussed previously.
To address the issue of small sample size and to increase power, we conducted analyses by
combining seropositive individuals for any of the four HPV types and compared them to
seronegative individuals for all four HPV types. These analyses did not indicate significantly
higher HR for subsequent HPV 16 incident infection, but for persistent HPV 18 infection a
significant protective effect was observed in adjusted models (aHR 0.42, 95% CI 0.19, 0.93)
(Table 2.5).
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Discussion:
In this study of men, baseline seropositive status was not associated with a reduction in
subsequent incident or six-month persistent HPV 6, 11, and 16 infections. In fact, HPV 16
seropositive men had a higher HPV 16 incident infection rate compared to HPV 16 seronegative
men. A possible protective effect was observed for HPV 18 persistent infections among
seropositive individuals, but the small number of infections requires a cautious interpretation of
these results. In general, natural immunity after HPV infection was not associated with a reduced
risk for subsequent HPV infections among men.
This is the first study to report a significantly higher risk of incident genital HPV 16
infections among seropositive men. In the few studies that have assessed the association of
antibodies generated following natural HPV infection and protection against subsequent genital
HPV infections in men, results have either been inconclusive or have not shown an association
(118, 119, 112). The current study is an extended analysis of previous work from our group
(118), in which we showed a non-significant increased risk for incident (aHR 1.22, 95% CI 0.83,
1.79) and persistent HPV 16 genital infections (aHR 1.05, 95% CI 0.51, 2.16).
The higher HPV 16 incidence among seropositive men was not observed consistently over
the entire follow-up period. Similar or lower genital HPV 16 incidence was observed among
seropositive and seronegative men up to the month 18 follow-up visit. Similar initial protective
effects against HPV 16 and other HPV genotypes have been documented among women,
followed by gradual waning of naturally induced IgG antibody levels over time (130-136). Highrisk sexual behavior among seropositive men, compared to seronegative men, may have led to
higher rates of incident infections among them. However, if this was the case, higher incidence
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among seropositive men should have been observed for other HPV types as well, and not just for
HPV 16. Although we adjusted for sexual behavior variables as time-varying covariates, there is
still a possibility that residual confounding occurred. There is also a possibility of not capturing
precise sexual behavior related risk due to error in reporting sexual behavior in the self-reported
questionnaire. Higher risk of incident and persistent infections among HPV 16 seropositive
individuals may also indicate possible reactivation of prior latent infection (137).
In this study, incident and persistent HPV 11 and 18 infections were generally lower
among seropositive subjects. Lower incidence (especially for persistent HPV 18) may be
suggestive of a transient protective effect, which gradually wanes after 18 months, as the KM
analyses indicated. However, due to the small number of HPV 18 events, this association failed
to reach statistical significance. Additional studies are needed to understand the role of anti-HPV
18 antibodies among men.
Factors including differential immune response by gender, differences in assay techniques,
and different durations of antibody levels have been suggested as possible explanations for the
difference in antibody response observed among men and women (118, 131, 138, 139).
Numerous studies have indicated a higher seroprevalence of both oncogenic and non-oncogenic
HPV types among women compared with men (140-146). A lower level of antibody response
following infection of keratinized epithelium among heterosexual men compared to mucosal
epithelial infection in heterosexual women may be a possible explanation for this gender
difference (118). Inclusion of non-neutralizing antibodies in our study may have led to
overestimation of overall serum antibody levels and may have biased the results toward the null.
Serum antibody cut-off levels may also affect the observed association. We therefore carried out
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analyses using the highest versus the lowest two tertiles of serum antibodies, and the results were
not substantially different.
To the best of our knowledge, our study is the first to assess the effect of serum antibody
status for all four major vaccine type HPVs in a large, multicenter cohort of men with a longterm follow-up. Despite these strengths, some limitations may have influenced the results. Serum
antibody levels were determined at a single baseline visit in our study. Men with prior exposure
may have been misclassified as seronegative due to lower seroconversion rates, waning antibody
response, and time-lag between exposure and antibody response. This misclassification is likely
to be non-differential and may have attenuated findings toward the null. Misclassification of
HPV infection is also a possibility, although we utilized robust methods for DNA detection that
are well-established (121). Furthermore, single baseline visit DNA negative subjects were
assumed to be the at risk population and were considered eligible for the study. We ran a
separate analysis using more stringent criteria of requiring two negative visits (baseline and first
six months visit) to qualify for entry into the analyses. Use of this stringent criterion also did not
alter study results.
We did not have information about infections that may have occurred prior to the study
start. These infections may not have cleared but instead remained latent at low copy numbers
(137). Latency for HPV infection has been described in animal models and recently, reactivation
of latent infection has been demonstrated among immuno-compromised individuals (137).
Assessment of previous infections is challenging, especially among men who have been sexually
active for a long period of time. Furthermore, current HPV DNA detection methods may not be
sensitive enough to detect low viral load of latent infection or reactivations that last for a short
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time period (118). Future studies are needed to explore the effect of latent HPV infections and
their reactivation among healthy individuals.
In conclusion, among men participating in the HIM study, baseline seropositivity after
natural infection with HPV 6, 11 and 16 was not associated with protection against subsequent
type-specific genital infection, with a possible protective effect against persistent HPV 18
infections. For HPV 16, a significantly higher risk of incident infection was observed among
seropositive men. The effect of anti-HPV antibodies may be influenced by duration of the
antibody response, time period between initial and subsequent genital infection, and overall
antibody levels. These results highlight the importance of HPV prevention measures, such as
vaccination, which are proven to protect against subsequent HPV infections and related genital
diseases.
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Table 2.1- Demographic characteristics of seronegative and HPV 6, 11, 16 and 18 seropositive HIM Study participants
HPV 6
Characteristics

Seronegative

Seropositive

HPV 11

HPV 16

HPV 18

Seronegative

Seropositive

Seronegative

Seropositive

Seronegative

Seropositive

Country
United States

1216 (96.4)

46 (3.6)

1249 (94.0)

80 (6.0)

1086 (88.6)

140 (11.4)

1209 (93.2)

88 (6.8)

Brazil

1173 (89.2)

142 (10.8)

1155 (83.1)

235 (16.9)

1047 (81.7)

234 (18.3)

1199 (87.0)

179 (13.0)

1149 (90.2)

125 (9.8)

1077 (81.2)

250 (18.8)

1176 (91.7)

107 (8.3)

1170 (87.6)

166 (12.4)

Mexico
a

p value

<0.0001

<0.0001

<0.0001

<0.0001

Age
18-30

1723 (93.1)

127 (6.9)

1740 (88.2)

232 (11.8)

1655 (90.9)

165 (9.1)

1786 (91.8)

159 (8.2)

31-44

1354 (90.6)

140 (9.4)

1296 (83.8)

250 (16.2)

1225 (83.6)

241 (16.4)

1366 (88.3)

181 (11.7)

45-73

461 (90.9)

46 (9.1)

445 (84.3)

83 (15.7)

429 (85.1)

75 (14.9)

426 (82.1)

93 (17.9)

p valuea

0.0209

<0.0001

<0.0001

<0.0001

Marital status
Single

1583 (92.6)

127 (7.4)

1606 (88.2)

214 (11.8)

1475 (87.9)

203 (12.1)

1612 (90.3)

174 (9.7)

Married/
Cohabitating

1628 (91.3)

156 (8.7)

1555 (83.9)

298 (16.1)

1544 (87.6)

218 (12.4)

1648 (88.8)

208 (11.2)

Divorced/Separated

307 (91.6)

28 (8.4)

300 (85.7)

50 (14.3)

272 (82.4)

58 (17.6)

296 (85.3)

51 (14.7)

a

p value

0.3578

0.0016

0.0217

0.0209

Race
Whites

1590 (93.3)

114 (6.7)

1587 (87.7)

223 (12.3)

1419 (85.2)

246 (14.8)

1606 (90.5)

169 (9.5)

African-Americans

547 (91)

54 (9.0)

561 (88.6)

72 (11.4)

486 (83.5)

96 (16.5)

547 (87.4)

79 (12.6)

105 (98.1)

2 (1.9)

105 (93.8)

7 (6.3)

100 (92.6)

8 (7.4)

101 (93.5)

7 (6.5)

1236 (89.8)

141 (10.2)

1171 (81.9)

258 (18.1)

1254 (90.9)

125 (9.1)

1265 (87.9)

174 (12.1)

Asian/Pacific
Islander
Mixed race/Others b
a

p value

<0.0001

<0.0001

<0.0001
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Table 2.1(Continued)
HPV 6
Seronegative Seropositive

HPV 11
Seronegative Seropositive

HPV 16
Seronegative Seropositive

HPV 18
Seronegative Seropositive

≤ 12 years

1689 (89.9)

189 (10.1)

1653 (83.8)

319 (16.2)

1622 (86.9)

244 (13.1)

1750 (88.8)

221 (11.2)

13-15 years

931 (95.0)

49 (5.0)

933 (91.3)

89 (8.7)

854 (89.9)

96 (10.1)

917 (90.9)

92 (9.1)

≥16 years

895 (92.5)

73 (7.5)

875 (85.3)

151 (14.7)

813 (85.5)

138 (14.5)

888 (88.4)

117 (11.6)

Characteristics

Education

p valuea
Alcohol use
Non-drinkers

<0.0001

<0.0001

0.1369

0.0113

834 (89.8)

95 (10.2)

822 (85.0)

145 (15.0)

803 (86.9)

121 (13.1)

846 (87.9)

117 (12.1)

<0.5 drinks/day

1173 (91.9)

103 (8.1)

1133 (85.1)

199 (14.9)

1110 (88.3)

147 (11.7)

1169 (88.3)

155 (11.7)

0.5-2 drinks/day

817 (93.1)

61 (6.9)

813 (87.4)

117 (12.6)

760 (88.1)

103 (11.9)

832 (91.3)

79 (8.7)

>2 drinks/day

563 (92.9)

43 (7.1)

566 (87.3)

82 (12.7)

506 (85.6)

85 (14.4)

574 (89.4)

68 (10.6)

p valuea
Cigarette smoking
Never

0.2322

0.0469

0.3649

0.0649

2059 (92.9)

158 (7.1)

2020 (87)

302 (13.0)

1912 (87.5)

272 (12.5)

2072 (90.2)

226 (9.8)

Former smoker

644 (91)

64 (9.0)

636 (85)

112 (15.0)

612 (86.9)

92 (13.1)

646 (86.8)

98 (13.2)

Current smoker

811 (90.3)

87 (9.7)

802 (84.4)

148 (15.6)

760 (86.8)

116 (13.2)

832 (88.5)

108 (11.5)

a

p value

Circumcision
No
Yes

0.1118

0.0244

0.8047

0.0302

2152 (90.2)

233 (9.8)

2078 (83.2)

421 (16.8)

2045 (86.8)

310 (13.2)

2195 (88.0)

299 (12.0)

1386 (94.5)

80 (5.5)

1403 (90.7)

144 (9.3)

1264 (88.1)

171 (11.9)

1383 (91.2)

134 (8.8)

a

p value

<0.0001

0.2636

<0.0001

0.0016

Sexual orientation
MSW

2664 (93.5)

186 (6.5)

2640 (88)

360 (12.0)

2504 (89.3)

300 (10.7)

2704 (91)

267 (9.0)

MSM

86 (76.8)

26 (23.2)

84 (72.4)

32 (27.6)

80 (71.4)

32 (28.6)

82 (70.7)

34 (29.3)

MSWM

325 (83.8)

63 (16.2)

312 (75.5)

101 (24.5)

291 (76.6)

89 (23.4)

328 (80.2)

81 (19.8)

p valuea

<0.0001

<0.0001

<0.0001
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<0.0001

Table 2.1(Continued)
HPV 6
Characteristics

Seronegative

Seropositive

HPV 11

HPV 16

HPV 18

Seronegative

Seropositive

Seronegative

Seropositive

Seronegative

Seropositive

Lifetime female
sexual partners
0-1 partners

764 (92.7)

60 (7.3)

487 (87.4)

70 (12.6)

483 (89.4)

57 (10.6)

518 (92.3)

43 (7.7)

2-9 partners

1171 (92.7)

92 (7.3)

1393 (86.6)

216 (13.4)

1362 (89.4)

162 (10.6)

1449 (90.8)

147 (9.2)

10-49 partners

1082 (92.6)

87 (7.4)

1080 (86.2)

173 (13.8)

987 (86.6)

153 (13.4)

1096 (88.5)

142 (11.5)

≥50 partners

193 (88.9)

24 (11.1)

201 (87)

30 (13.0)

171 (80.7)

41 (19.3)

192 (85.3)

33 (14.7)

a

p value

0.2589

0.9058

0.0010

0.0041

New female
partners in past 3-6
months
None

2020 (92.3)

169 (7.7)

1982 (86.6)

306 (13.4)

1898 (87.7)

265 (12.3)

2027 (89.5)

238 (10.5)

1 partner

809 (93.1)

60 (6.9)

804 (86.7)

123 (13.3)

768 (89.6)

89 (10.4)

835 (90.6)

87 (9.4)

≥2 partners

389 (93.3)

28 (6.7)

392 (88.5)

51 (11.5)

343 (85.3)

59 (14.7)

395 (91.0)

39 (9.0)

a

p value

0.6271

0.5583

0.0838

0.4886

Lifetime male
sexual partners
None

2765 (93.6)

188 (6.4)

2745 (88.2)

366 (11.8)

2602 (89.6)

302 (10.4)

2808 (91.2)

270 (8.8)

1-9 partners

306 (87.4)

44 (12.6)

299 (80.2)

74 (19.8)

282 (81.5)

64 (18.5)

317 (85.9)

52 (14.1)

≥10 partners

105 (70.0)

45 (30.0)

97 (62.2)

59 (37.8)

89 (61)

57 (39.0)

93 (59.6)

63 (40.4)

a

p value

<0.0001

<0.0001

<0.0001

<0.0001

New male partners
in past 3 months
None

3054 (92.7)

239 (7.3)

3015 (87)

450 (13)

2865 (88.6)

370 (11.4)

3100 (90.4)

329 (9.6)

1 partner

57 (77)

17 (23.0)

59 (72)

23 (28.0)

51 (67.1)

25 (32.9)

60 (72.3)

23 (27.7)

≥2 partners

64 (72.7)

24 (27.3)

66 (70.2)

28 (29.8)

57 (66.3)

29 (33.7)

56 (60.9)

36 (39.1)

a

p value

<0.0001

<0.0001

<0.0001
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<0.0001

Footnotes:
Abbreviation: HPV, human papillomavirus; MSM, men who have sex with men; MSW, men who have sex with women; MSWM, men who
have sex with women and men

a - p-values for categorical variables were calculated using the chi-square test with Monte Carlo estimation of p-values, α = 0.05.
b - Includes mixed race, American Indians, Alaska natives, Native Hawaiians or other races
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Table 2.2a –HPV6, 11, 16 and 18 incidence proportions during 4 years follow-up in HIM Study
HPV 6

Time of DNA

HPV 11

HPV 16

HPV 18

At riska

N

IP (95% CI) b

At riska

N

IP (95% CI) b

At riska

N

IP (95% CI) b

At riska

N

IP (95% CI) b

Seronegative

2371

47

1.98 (1.42, 2.54)

2384

13

0.55 (0.25, 0.84)

2227

45

2.02 (1.44, 2.61)

2454

26

1.06 (0.65, 1.46)

Seropositive

214

5

2.34 (0.31, 4.36)

393

0

0.00 (NA)

316

7

2.22 (0.59, 3.84)

298

0

0.00 (NA)

Seronegative

2615

53

2.03 (1.49, 2.57)

2681

22

0.82 (0.48, 1.16)

2443

52

2.13 (1.56, 2.70)

2717

32

1.18 (0.77, 1.58)

Seropositive

233

6

2.58 (0.54, 4.61)

437

2

0.46 (0.18, 1.09)

364

5

1.37 (0.18, 2.57)

333

2

0.60 (0.23, 1.43)

Seronegative

2539

58

2.28 (1.70, 2.87)

2607

14

0.54 (0.26,0.82)

2382

55

2.31 (1.71, 2.91)

2673

33

1.23 (0.82, 1.65)

Seropositive

228

4

1.75 (0.05, 3.46)

434

1

0.23 (0.22, 0.68)

345

5

1.45 (0.19, 2.71)

322

5

1.55 (0.20, 2.90)

Seronegative

2436

29

1.19 (0.76, 1.62)

2528

15

0.59 (0.29, 0.89)

2249

60

2.67 (2.00, 3.33)

2554

23

0.90 (0.53, 1.27)

Seropositive

201

4

1.99 (0.06, 3.92)

406

3

0.74 (0.09, 1.57)

337

17

5.04 (2.71, 7.38)

319

4

1.25 (0.03, 2.48)

Seronegative

2258

33

1.46 (0.97, 1.96)

2376

10

0.42 (0.16, 0.68)

2089

28

1.34 (0.85, 1.83)

2417

22

0.91 (0.53, 1.29)

Seropositive

194

3

1.55 (0.19, 3.28)

401

2

0.50 (0.19, 1.19)

292

9

3.08 (1.10, 5.06)

279

0

0.00 (NA)

Seronegative

2215

32

1.44 (0.95, 1.94)

2329

12

0.52 (0.22, 0.81)

2031

44

2.17 (1.53, 2.80)

2351

18

0.77 (0.41, 1.12)

Seropositive

205

4

1.95 (0.06, 3.84)

392

2

0.51 (0.20, 1.22)

297

10

3.37 (1.32, 5.42)

303

3

0.99 (0.12, 2.10)

Seronegative

1938

24

1.24 (0.75, 1.73)

2058

18

0.87 (0.47, 1.28)

1741

32

1.84 (1.21, 2.47)

2072

16

0.77 (0.40, 1.15)

Seropositive

157

2

1.27 (0.48, 3.03)

347

7

2.02 (0.54, 3.50)

242

10

4.13 (1.62, 6.64)

275

4

1.45 (0.04, 2.87)

Seronegative

1716

31

1.81 (1.18, 2.44)

1863

4

0.21 (0.00, 0.42)

1581

32

2.02 (1.33, 2.72)

1846

16

0.87 (0.44 , 1.29)

Seropositive

158

1

0.63 (0.60, 1.87)

321

0

0.00 (NA)

245

6

2.45 (0.51, 4.38)

248

3

1.21 (0.15, 2.57)

Seronegative

559

12

2.15 (0.95, 3.35)

623

3

0.48 (1.97, 2.32)

526

14

2.66 (1.29, 4.04)

628

14

2.23 (1.07, 3.38)

Seropositive

37

1

2.70 (2.52, 7.93)

93

0

0.00 (NA)

55

1

1.82 (1.70, 4.37)

64

1

1.56 (1.48, 4.60)

detection
0-6 months

7-12 months

13-18 monthsc

19-24 months

25-30 months

31-36 months

37-42 months

43-48 months

>48 months
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Footnotes –
Abbreviations: HPV-human papilloma virus; IP-Incidence proportion, CI-confidence interval; NA-Not Applicable, Sero- = Seronegative, Sero+ = Seropositive
a - No. at risk was defined as number of men followed till the stated duration, who were HPV DNA negative for particular HPV type at the beginning of time interval
b - Percentage was defined as the number of incident infection over the number of participants at risk that occurred at each time interval
c - Participants who were late (1st follow-up visit after six months), were included in successive time interval based on the visit date, which led to higher numbers for second
follow-up period.
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Table 2.2b – HPV 6, 11, 16 and 18 incident persistent infections during 4 years follow-up in HIM Study
HPV 6
Time of DNA

At

HPV 11
At

HPV 16
At

HPV 18
At

riska

N

IP (95% CI) b

riska

N

IP (95% CI) b

riska

N

IP (95% CI) b

riska

N

IP (95% CI) b

Seronegative

2012

11

0.55 (0.22, 0.87)

2035

7

0.34 (0.09, 0.60)

1885

15

0.80 (0.39, 1.20)

2079

8

0.38 (0.12, 0.65)

Seropositive

174

1

0.57 (0.55, 1.70)

332

0

0.00 (NA)

277

2

0.72 (0.28, 1.72)

256

0

0.00 (NA)

Seronegative

2539

22

0.87 (0.51, 1.23)

2571

4

0.16 (0.00, 0.31)

2389

26

1.09 (0.67, 1.50)

2657

16

0.60 (0.31, 0.90)

Seropositive

233

2

0.86 (0.33, 2.04)

431

0

0.00 (NA)

344

2

0.58 (0.22, 1.38)

315

0

0.00 (NA)

Seronegative

2464

17

0.69 (0.36, 1.02)

2530

8

0.32 (0.10, 0.53)

2302

28

1.22 (0.77, 1.66)

2561

18

0.70 (0.38, 1.03)

Seropositive

202

1

0.50 (0.47, 1.46)

398

0

0.00 (NA)

337

4

1.19 (0.03, 2.34)

319

1

0.31 (0.30, 0.93)

Seronegative

2283

16

0.70 (0.36, 1.04)

2380

5

0.21 (0.03, 0.39)

2120

13

0.61 (0.28, 0.95)

2435

10

0.41 (0.16, 0.66)

Seropositive

199

2

1.01 (0.38, 2.39)

402

0

0.00 (NA)

305

3

0.98 (0.12, 2.09)

283

0

0.00 (NA)

Seronegative

2248

12

0.53 (0.23, 0.84)

2340

5

0.21 (0.03, 0.40)

2061

13

0.63 (0.29, 0.97)

2371

6

0.25 (0.05, 0.46)

Seropositive

207

1

0.48 (0.46, 1.43)

395

1

0.25 (0.24, 0.75)

311

3

0.96 (0.12, 2.05)

303

0

0.00 (NA)

Seronegative

1956

6

0.31 (0.06, 0.55)

2062

3

0.15 (0.02, 0.31)

1773

15

0.85 (0.42, 1.27)

2082

7

0.34 (0.09, 0.58)

Seropositive

160

0

0.00 (NA)

353

1

0.28 (0.27, 0.84)

252

4

1.59 (0.04, 3.13)

275

0

0.00 (NA)

Seronegative

1737

12

0.69 (0.30, 1.08)

1869

4

0.21 (0.00, 0.42)

1600

9

0.56 (0.20, 0.93)

1857

6

0.32 (0.06, 0.58)

Seropositive

159

0

0.00 (NA)

321

0

0.00 (NA)

248

2

0.81 (0.31, 1.92)

252

0

0.00 (NA)

Seronegative

569

4

0.70 (0.02, 1.39)

627

1

0.16 (0.15, 0.47)

536

1

0.19 (0.18, 0.55)

634

3

0.47 (0.06, 1.01)

Seropositive

37

0

0.00 (NA)

95

0

0.00 (NA)

60

1

1.67 (1.57, 4.91)

65

1

1.54 (1.45, 4.53)

detection

7-12 months

13-18 monthsc

19-24 months

25-30 months

31-36 months

37-42 months

43-48 months

>48 months
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Footnotes –
Abbreviations: HPV, human papilloma virus; CI, confidence interval; NA, Not Applicable
a - No. at risk was defined as number of men followed till the stated duration, who were HPV DNA negative or positive for particular HPV type at the beginning of each time
interval
b - Percentage was defined as the number of incident infection over the number of participants at risk that occurred at each time interval
c - Participants who were late (1st follow-up visit after six months), were included in successive time interval based on the visit date, which led to higher numbers for second
follow-up period.
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Table 2.3 - Crude and adjusted hazard ratios (HR) according to sero-status for incident HPV 6, 11, 16 and 18 infections among
HIM Study participants
No. of men
Incident
infection
HPV 6
Seronegative
Seropositive
HPV 11
Seronegative
Seropositive
HPV 16
Seronegative
Seropositive
HPV 18
Seronegative
Seropositive
6 month
persistent
infection
HPV 6
Seronegative
Seropositive
HPV 11
Seronegative
Seropositive
HPV 16
Seronegative
Seropositive
HPV 18
Seronegative
Seropositive

No. of infections Crude HR and 95% CI

Adjusted HR and 95% CI

3105
283

319
30

1.00
1.08 (0.74, 1.56)

1.00
0.91 (0.56, 1.48)a

3132
513

111
17

1.00
0.92 (0.55, 1.54)

1.00
0.80 (0.44, 1.45)b

2912
420

362
70

1.00
1.40 (1.08, 1.81)

1.00
1.37 (1.01, 1.86)c

3202
391

200
22

1.00
0.92 (0.59, 1.43)

1.00
0.90 (0.531, 1.57)d

3105
283

100
7

1.00
0.80 (0.37, 1.73)

1.00
0.98 (0.39, 2.46)e

3132
513

37
2

1.00
0.32 (0.08, 1.34)

1.00
0.31 (0.04, 2.30)f

2912
420

120
21

1.00
1.26 (0.79, 2.01)

1.00
1.39 (0.80, 2.41)g

3202
391

74
2

1.00
0.22 (0.06, 0.91)

1.00
0.19(0.03 1.37)h
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Footnotes: HPV- Human Papillomavirus, HR- Hazard ratios
a - Adjusted for marital status, alcohol use, lifetime male sexual partners (time varying), and new female partners in past 6-12 months (time
varying).
b - Adjusted for marital status, race, lifetime female sexual partners (time varying), and new male partners in past 6-12 months (time varying).
c - Adjusted for age, marital status, lifetime female sexual partners (time varying), lifetime male sexual partners (time varying), and new female
partners in past 6-12 months (time varying).
d - Adjusted for country, alcohol use, lifetime male sexual partners (time varying), and new female partners in past 6-12 months (time varying).
e - Adjusted for age, alcohol use, new female partners in past 6-12 months (time varying) and frequency of sexual intercourse with female partners
in past 6-12 months.
f - Adjusted for age, alcohol use, new female partners in past 6-12 months (time varying) and new male partners in past 6-12 months (time
varying)
g - Adjusted for age, country, lifetime male sexual partners (time varying) and new female partners in past 6-12 months (time varying)
h - Adjusted for marital status, alcohol use, lifetime male sexual partners (time varying), and new female partners in past 6-12 months (time
varying).
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Table 2.4 - Crude and adjusted hazard ratios (HR) stratified by sexual orientation for incident
HPV 16 and 18 infections among HIM Study participants
HPV 16
At
risk

N

Crude HR

Incident
infections
MSW
Seronegative
Seropositive

2204
261

269
42

MSWM
Seronegative
Seropositive

268
82

MSM
Seronegative
Seropositive

HPV 18
Adjusted HR

At
risk

N

Crude HR

Adjusted HR

1.0
1.37 (0.99, 1.90)

1.0
1.31(0.90,1.93)a

2419
242

138
11

1.0
0.82 (0.45, 1.52)

1.0
1.01 (0.51, 2.01)d

47
14

1.0
1.06 (0.58, 1.93)

1.0
0.88 (0.45, 1.73)b

305
73

27
7

1.0
1.12 (0.49, 2.56)

1.0
1.02 (0.41, 2.58)e

75
27

12
6

1.0
1.33 (0.50, 3.55)

1.0
1.61 (0.58, 4.53)c

78
31

10
2

1.0
0.44 (0.09, 2.03)

1.0
0.98 (0.17, 5.67)c

Six month
persistent
infections
MSW
Seronegative
Seropositive

2204
261

93
15

1.0
1.42 (0.82, 2.44)

1.0
1.46 (0.79, 2.73)f

2419
242

53
1

1.0
0.19 (0.03, 1.41)

1.0
0.25 (0.03,1.84)i

MSWM
Seronegative
Seropositive

268
82

13
3

1.0
0.83 (0.24, 2.93)

1.0
0.85 (0.24, 3.00)g

305
73

9
1

1.0
0.49 (0.06, 3.84)

1.0
0.51 (0.06, 4.03)h

MSM
Seronegative
Seropositive

75
27

5
1

1.0
0.54 (0.06, 4.60)

1.0
0.58 (0.07, 4.97)h

78
31

1
0

1.0
NE

1.0
NE

Footnotes:
HPV- Human Papillomavirus, HR- Hazard ratios, MSW- Men who have sex with women, MSWM- Men who have sex with women and men, MSM- Men
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who have sex with men
a-Adjusted for race, alcohol use, lifetime female partners (time varying) and new female partners in past 6-12 months(time varying)
b-Adjusted for marital status, alcohol use, new female partners in past 6-12 months(time varying) and new male partners in past 6-12 months(time varying)
c - Adjusted for new male partners in past 6-12 months(time varying)
d- Adjusted for marital status, alcohol use, new female partners in past 6-12 months(time varying) and frequency of sexual intercourses in past 6-12
months(time varying)
e- Adjusted for age, new male partners in past 6-12 months(time varying) and frequency of sexual intercourse with female partners in past 6-12
months(time varying)
f-Adjusted for age, country, and new female partners in past 6-12 months(time varying)
g- Adjusted for country
h- Adjusted for age
i- Adjusted for marital status, lifetime female partners(time varying) and new female partners in past 6-12 months(time varying)
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Table 2.5: Crude and adjusted hazard ratios (HR) according to seropositive for any four HPV types (HPV 6,
11, 16 and 18) compared to seronegative for all four types infections among men in the HIM study
No. of men
Incident infection
HPV 6
Seronegativea
Seropositiveb
HPV 11
Seronegativea
Seropositiveb
HPV 16
Seronegativea
Seropositiveb
HPV 18
Seronegativea
Seropositiveb
6 month persistent
infection
HPV 6
Seronegativea
Seropositiveb
HPV 11
Seronegativea
Seropositiveb
HPV 16
Seronegativea
Seropositiveb
HPV 18
Seronegativea
Seropositiveb

No. of
infections

Crude HR and 95% CI

Adjusted HR and 95% CI

2663
1082

240
109

1.00
1.12 (0.90, 1.41)

1.00
1.08(0.81, 1.43)c

2858
1164

88
40

1.00
1.12 (0.77, 1.63)

1.00
0.89 (0.55, 1.42)d

2609
1062

307
125

1.00
1.01 (0.82, 1.24)

1.00
1.08 (1.84, 1.39)e

2803
1158

157
65

1.00
1.00 (0.75, 1.34)

1.00
1.09 (0.77, 1.54)f

2663
1082

83
24

1.00
0.72 (0.46, 1.13)

1.00
0.82 (0.48, 1.40)g

2858
1164

30
9

1.00
0.73 (0.35, 1.54)

1.00
0.49 (0.17, 1.44)h

2609
1062

101
40

1.00
0.98 (0.68, 1.41)

1.00
1.27(0.83, 1.92)i

2803
1158

64
12

1.00
0.45 (0.24, 0.84)

1.00
0.42 (0.19, 0.93)j

Footnote: HPV- Human Papillomavirus, HR- Hazard ratios
a – Seropositive for any of the 4 HPV types (HPV 6, 11, 16 and 18)
b – Seronegative for all 4 HPV types (HPV 6, 11, 16 and 18)
c- Adjusted for marital status, alcohol use, lifetime male sexual partners (time varying), and new female partners in past 6-12 months (time
varying).
d- Adjusted for country, lifetime male sexual partners (time varying), and new female partners in past 6-12 months (time varying).
e - Adjusted for country, lifetime female sexual partners (time varying), lifetime male sexual partners (time varying), and new female
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partners in past 6-12 months (time varying).
f- Adjusted for marital status, alcohol use, lifetime male sexual partners (time varying), and new female partners in past 6-12 months (time
varying).
g - Adjusted for age, alcohol use and new female partners in past 6-12 months (time varying).
h - Adjusted for new female partners in past 6-12 months (time varying) and new male partners in past 6-12 months (time varying).
i - Adjusted for age, country and new female partners in past 6-12 months (time varying)
j - Adjusted for marital status, lifetime female sexual partners (time varying), and new female partners in past 6-12 months (time varying).
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Figure 2.1 - Kaplan-Meier curves for acquisition of incident HPV 6, 11, 16, and 18 infections by serostatus among men in the HIM
Study
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Footnotes:
Serum status: Solid line = Seronegative subjects, Dashed line= Seropositive subjects
P values were determined using the log-rank test and denote differences across the entire follow-up period, by serum status. Values < .05
are considered statistically significant
Median failure times were 47.6 months (HPV 6), 48.6 months (HPV 11), 47.9 months (HPV 16) and 48.5 months (HPV 18).
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Figure 2.2 - Kaplan-Meier curves for acquisition of six-month persistent HPV 6, 11, 16, and 18 infections by serostatus among men
in the HIM Study
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Footnotes:
Serum status: Solid line = Seronegative subjects, Dashed line= Seropositive subjects
P values were determined using the log-rank test and denote differences across the entire follow-up period, by serum status. Values < .05
are considered statistically significant
Median failure times were 47.8 months (HPV 6), 48.7 months (HPV 11), 48.0 months (HPV 16) and 48. 6 months (HPV 18).
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MANUSCRIPT TWO

Introduction:
Human Papillomavirus (HPV) infection is one of the most common sexually transmitted
infections in men and women (147). The Human Papillomavirus Infection in Men (HIM) Study
was among the first to report the natural history of genital HPV infection among men (147, 148).
In this study, average duration of a genital HPV infection was ~7.5 months for any HPV
infection and 12.2 months for HPV 16 infection (147). After initial clearance (≥ 12 month time
without detection of HPV DNA), individuals were susceptible for recurrence/redetection of HPV
infection with the same HPV type. Recurrent HPV infection is an important component of the
natural history of these infections and may help to elucidate the anogenital HPV prevalence
observed among men in numerous studies (147, 139-152).
No studies have evaluated HPV recurrence in men and only a few have examined the
recurrence of cervical HPV infection among women. In studies among women, 18.1-19.5% of
HPV infections were redetected (153-157). High risk sexual behaviors, such as having multiple
sexual partners and new sexual partners, were reported as some of the most important risk factors
associated with redetection of cervical HPV infection (153, 157). However, sexual behavior did
not explain all the infection recurrences observed in women.
In the current study, we assessed recurrence of nine HPV vaccine types (HPV 6, 11, 16,
18, 31, 33, 45 52 and 58) in the HIM Study cohort (n= 4,123). Our objective was to estimate
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type-specific recurrence of genital HPV infections and investigate factors associated with
recurrence among men.
Methods:
Study population
The HPV Infection in Men (HIM) Study is a study of the natural history of HPV among
men in Tampa, Florida (U.S.), São Paulo (Brazil), and Cuernavaca (Mexico). Detailed methods
and recruitment of study participants has been described previously (148). Briefly, healthy men
from each study site were followed every six months for a median follow-up time of four years.
Eligibility criteria for the participants were : i) 18–70 years of age; ii) residents of one of the
study sites; iii) no previous diagnosis of penile or anal cancers; iv) no previous diagnosis of
genital or anal warts; v) no symptoms of a sexually transmitted infection (STI) and not receiving
treatment for an STI; vi) not participating in an HPV vaccine study; vii) no history of HIV or
AIDS; viii) no history of imprisonment, homelessness, or drug treatment during the past six
months; and ix) willing to comply with 10 scheduled visits every six months for four years with
no plans to relocate during that time. Questionnaires were administered using computer-assisted
self-interviewing (CASI) at baseline and each follow-up visit to obtain extensive sexual history
and health information. All eligible participants provided signed informed consent, and approval
was obtained from the human subjects committees of the University of South Florida (Tampa,
FL), Ludwig Institute for Cancer Research (São Paulo, Brazil), Centro de Referencia e
Treinamento em Doencas Sexualmente Transmissíveis e AIDS (São Paulo, Brazil), and Instituto
Nacional de Salud Publica de Mexico (Cuernavaca, Mexico).
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External genital HPV DNA samples
Genital cell samples from the coronal sulcus/glans penis, penile shaft, and scrotum were
collected with three prewetted Dacron swabs, which were later combined to form a single sample
(147, 148). Specimens were stored at -80°C, until analyses. The QIAamp DNA Blood Mini Kit
(QIAGEN) was used to extract DNA and HPV DNA tests were performed using PCR
amplification of the L1 gene fragment of HPV. Thirty seven different types of genital HPV were
detected with use of the Roche Linear Array assay for HPV genotyping (158). Human β-globin
was tested to assess specimen adequacy, with an overall β-globin positivity of 98%.
Statistical analysis
The nine HPV types (HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58) in the recently approved
nonavalent HPV vaccine were included in this analysis (159). Participants with prevalent HPV
infections at baseline or an incident infection during the follow-up period were eligible for
inclusion in the study. Participants who were HPV DNA negative throughout the entire study
period, those with prevalent infections that persisted throughout the entire study period or
incident infections that persisted throughout the remaining follow-up time, and participants who
dropped out of the study before infection clearance were excluded from the analysis (Figure 3.1).
Two different analyses were carried out: 1) individual HPV type analysis for each of the nine
genotypes (infection-level type-specific analysis), and 2) grouped analyses (recurrent infection
vs. non-recurrent infection with any of the 9 vaccine types). Recurrences assessed in both of
these analyses were genotype concordant (type-specific). For example, after clearance of HPV
16 infection, recurrence of HPV 16 was assessed in the analyses.
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In individual HPV type (type-specific) analyses, infections were categorized into two
groups: a) infections that were first observed as incident and b) infections observed as prevalent
at the baseline visit. Both these groups were further categorized by infection duration; transient
(observed at one visit only) and persistent (infection with duration of > 6 months). Infection
recurrence was defined as reappearance/redetection of DNA of the same HPV genotype after two
successive DNA-negative tests at clinical visits scheduled at 6-month intervals (>12 months
duration). Figure 1 describes the study participants excluded and included in this analysis and
definitions of the analytical groups.
For each HPV genotype, the proportion of infections that recurred among individuals with
a prior incident or prior prevalent infection was calculated. Visit-specific questionnaire data
corresponding to the two successive 6 month study visits following the last visit when that
specific HPV DNA was detected (12-month at risk period for recurrence) were utilized in
analyses for men whose infections did not recur. For men whose infections did recur,
questionnaire data from the visit where the recurrence was observed (as behavior was inquired
for the prior 6 months) and data reported on the visit prior to the recurrence (total time period up
to 12 months prior to the recurrence) were utilized in analyses. Variables of interest for these
analyses included sexual behavior, tobacco, alcohol use, and factors previously shown to be
associated with genital incidence and prevalence in the HIM Study cohort (147, 148).
Grouped analysis was carried out to increase the power to assess associations between
overall recurrence and related risk factors. If individuals had recurrent infection of any of the 9
HPV types; they were grouped as “Recurrent infections for any type”. Individuals in the “Nonrecurrent infections” group did not have recurrences of any of the 9 HPV types. Subjects were
further categorized into three groups: i) only incident infection with any of the nine types ii) only
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prevalent infection with any of the nine types, and iii) a combination of prevalent and incident
infection with any of the nine types. Demographic characteristics for these groups were
compared using Chi-square tests with Monte Carlo estimation of exact p-values. In the grouped
analysis men who had multiple HPV infections, “at risk period for recurrence” differed across
infections in men. Therefore, we characterized individual behavior based on participants’ overall
pattern of responses throughout the study follow-up for sexual behavior, tobacco, and alcohol
use questions. Logistic regression was utilized to evaluate the association between these
variables and infection recurrence. Behavioral factors, along with demographic variables, were
evaluated in adjusted models. Selection of variables for inclusion in final model was based on
the Akaike information criteria (AIC) values.
Results:
Genital DNA samples were available for 4,123 participants of the HIM study at baseline.
For type-specific analyses, subjects were excluded (HPV6 = 621, HPV11 =171, HPV16 = 762,
HPV18 = 300, HPV31 = 226, HPV33 = 76, HPV45 = 268, HPV52 = 486, and HPV58 =
292) if they were HPV DNA negative throughout the study follow-up, had persistent infection
throughout the duration of their follow-up time or dropped out before clearing the infection.
After these exclusions, 1,119 men with incident and 1,106 men with prevalent infections of one
or more of the nine vaccine type HPVs were included in analyses. Median duration of follow-up
was 3.7 years (range 0.4-7.4 years, mean 3.6 years, IQR 3.4-4.0).
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A) Individual HPV type recurrence
Overall, men whose initial infections were prevalent had higher recurrences compared to
men with initial incident infections (Figure 3.2). Recurrence proportions and factors associated
with recurrence of prevalent and incident infections are as follows.
Prevalent infections
Men with prior transient prevalent infections had recurrences ranging from 3.9%-31.2%,
while men with prior persistent prevalent infections had recurrence ranging from 10.8%-36.8%.
Among men with a prior transient prevalent infection, HPV 52 infection had the highest rate of
recurrence (31.2%), followed by HPV 45 (22.9%), HPV 58 (21.4%), HPV 6 (19.8%), and HPV
16 (19.6%) [Table 3.1a]. Among men with a prior persistent prevalent infection, HPV 45 had
the highest rate of recurrence (36.8%), followed by HPV 52 (32.4%), HPV 16 (23.5%), and
HPV6 (21.9%). Overall, persistent prevalent infections had higher recurrences compared to
prevalent infections that were initially transient. The average cleared time between the initial
prevalent infection (regardless of whether it was transient or persistent) and the recurrent
infection was 20.2 months for HPV 6, 17.2 months for HPV 11, 21.5 months for HPV 16, 18.7
months for HPV 18, 26.2 months for HPV 31, 22.5 months for HPV 33, 22.1 months for HPV
45, 25.4 months for HPV 52, and 21.3 months for HPV 58.
Incident infections
Recurrence of infections that were detected first as incident infections ranged from 0.0%19.7% for transient incident infections compared to 0.0%-26.3% among men whose prior
incident infections were persistent. Among men whose incident infections were initially
transient, the highest rate of recurrence was for HPV 58 (19.7%), followed by HPV 52 (14.6%),
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HPV 18 (12.6%) and HPV 16 (11.8%) [Table 3.1b]. Among men whose prior incident infections
were persistent, the highest recurrence was observed for HPV 11 (26.3%), followed by HPV 52
(24.5%), HPV18 (17.6%) and HPV 45 (13.6%). Similar to what was observed among prevalent
genital HPV infections, incident infections that were persistent had higher rates of recurrence
compared to incident infections that were transient. The average time between clearance of the
incident infection (regardless of whether it was transient or persistent) and detection of the
recurrence was 16.8 months (HPV 6), 18.2 months (HPV 11), 18.6 months (HPV 16), 17.4
months (HPV 18), 18.7 months (HPV 31), 19.1 months (HPV 33), 21.3 months (HPV 45), 18.9
months (HPV 52), and 15.2 months (HPV 58).
Factors associated with genital HPV infection recurrence
Sexual behavior variables were consistently associated with recurrence of infection,
regardless of whether the initially detected infection was prevalent or incident. Among men with
initial prevalent infections, HPV 6 infection recurrence was significantly associated with having
>=2 new female partners in previous 6-12 months (Table 3.2a). HPV 16 recurrence was
associated with higher frequency of sexual intercourse with female partners (>30 times) in the
past 6-12 months. For HPV 31, men who reported having a new female sexual partner had higher
rates of recurrence (38.5%), compared to men who did not report a new sexual partner (Table
3.2b). Recurrence of HPV 58 was highest among men consuming <0.5 drinks of alcohol per day.
Among men whose initially detected infections were incident, having one or more new
male sexual partners in the previous 6-12 months was significantly associated with higher
recurrence of HPV 16 infections (p= 0.01, Table 3.3a). Additionally, current smokers had the
highest proportion of HPV 16 recurrence (18.6%), although this association did not reach
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statistical significance (p= 0.06). Significantly higher rates of HPV 52 recurrence were observed
among former smokers (27.3%) compared to current smokers (p= 0.04, Table 3.3b). HPV 58
recurrence was associated with higher frequency of sexual intercourse (>30 times) with female
partners in past 6-12 months, but this association did not reach statistical significance (p = 0.09).
B) HPV infection recurrence in grouped analysis
In grouped analyses, numbers of men included in each of the three groups were, 635 (only
incident infection of any of the nine types), 641 (only prevalent infection of any of the nine
types), and 261 (mixed infections or combination of prevalent and incident infections) [Figure
3.3]. In this analysis, 13.4% men with prior incident infections had recurrence of any of the nine
HPV types. In comparison, 24.6% of men with prior prevalent infections had recurrence of any
of the nine HPV types. The highest rates of recurrence were observed among men who in the
past had a combination of both an incident and prevalent infections of different types (43%).
White men had the highest proportion (17.6%) of incident infections that recurred (p= 0.036,
Table 3.4). Recurrence of incident infections was also higher among men with a greater number
of lifetime male sexual partners (p= 0.012) and a greater number of new male partners (p=
0.011). Among men with combination of incident/prevalent infections, men with circumcision
had higher recurrence compared to the uncircumcised men (p= 0.011). Among men with initially
prevalent infections, none of the considered variables were significantly associated with infection
recurrence.
In logistic regression models (Table 3.5) utilizing overall behavior of the participants
during the follow-up period, statistically significant associations (adjusted odds ratios= aOR)
were observed with lifetime number of male sexual partners (aOR = 2.40, 95% CI 1.19-4.84) and
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number of new male sexual partners (aOR 2.35, 95% CI 1.16-4.74) among men who previously
only had an incident infection detected. Among men with a prior prevalent infection, moderate
alcohol consumption (0.5-<1.5 drinks per day) was significantly associated with a higher risk of
recurrence (aOR= 1.59, 95% CI 1.01, 2.53) compared to mild alcohol consumption (<0.5
drinks/day). Among men with combination of prior incident and prevalent infections, none of the
considered variables yielded statistically significant results.
Discussion:
This is the first study to report recurrence of nine vaccine type (HPV 6, 11, 16, 18, 31, 33,
45, 52, and 58) genital HPV infections among men. Our results indicate that as many as 31.2%
of genital HPV infections recur with the same type, with higher rates of recurrence for oncogenic
HPV types (HPV 16, 18, 45, 52, and 58).
In the current analysis, a higher number of new male sexual partners was consistently
associated with higher rates of recurrence of incident infections in both type-specific (HPV 16)
analyses as well as grouped analyses. Other high-risk sexual behaviors (higher number of new
female partners and frequency of sexual intercourse) were also associated with higher rates of
recurrence of initially prevalent HPV 6, 16 and 31 infections. Recurrence significantly differed
by smoking and alcohol use only for HPV types 16, 52, and 58. As no prior study has described
genital HPV recurrence among men, it is unclear with the rates reported here are unique to the
cohort, or geographic regions of study.
Among women, only a few studies have examined the recurrence of cervical HPV
infection. One study found that 19.4% of incident infections of multiple genotypes were
redetected within a year (154). A study examining specific HPV types reported a range of 0-16%
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recurrent HPV infections, with up to 11% of HPV 16 infections reappearing after 3 years (155).
A study by Moscicki et al. observed that HPV 16 DNA was redetected in 18.1% women after
clearance of initial infection (156). This study also reported that having one or more sexual
partners (aOR= 2.90, 95% CI 1.22, 6.90) and having a new sexual partner in the past eight
months (aOR= 1.1, 95% CI 1.02, 1.19) were associated with increased risk of redetection (156).
Another study observed an association between recurrence and having new sexual partners with
relative risk (RR) estimate of 3.7 (95% CI=1.1–13.8) for all HPV types included in the analysis
(153). These results are comparable to our findings of recurrence of HPV infection among men.
In contrast, lower rates of recurrence were observed (7.7% women with intervening negative
results and 2.7% women with definite clearance) in a study that included multiple carcinogenic
HPV types (157).
We observed higher rates of recurrence among participants with prior prevalent infections
and prior persistent infections (either incident or prevalent). Baseline prevalent infections had a
relatively longer observation period to allow for clearance and re-detection compared infections
detected as incident at some point in the follow-up period. As a result, there were more
recurrence events and greater power to assess associations with infections initially detected as
prevalent. This may partially explain the higher rates of recurrence for prior prevalent infections.
It is also likely that individuals with pre-existing infections had high risk sexual behavior and as
a result were at higher risk of re-acquiring of HPV infections. Similarly, individuals with
persistent infections may have engaged in high risk sexual behaviors, but due to the small sample
size, we were unable to carry out separate analyses comparing transient and persistent infections
for sexual behavior variables.
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There are three possible explanations for observed rates of HPV infection recurrence: a)
sexual exposure from the same partner who has not cleared the infection; b) exposure to a new
partner who is infected with the same HPV type; and c) reactivation of latent infections. Our
results show that new male partners, new female partners, and higher numbers of lifetime sexual
partners lead to higher genital HPV infection recurrence. We do not, however, have information
to differentiate whether the recurrence was acquired from a new partner or from the same
partner. Partner studies as well as perhaps evaluation of HPV status with next generation
sequencing are needed to shed light on the origin of the recurrent infections. However, intratypic variant analysis may not identify the source of infection, as specific HPV variants are more
prevalent in a particular geographic area (160-162); thus probability of infection from a new
source is highest for the prevalent variant circulating in the community. In addition, current
methods can not differentiate between latent and newly acquired infections (163). Thus, analysis
of recurrent infection presents a number of challenges and logistic issues.
Strengths of this study include large sample size, multinational nature of the cohort, and
long follow-up time. Additionally, standard and robust HPV DNA genotyping measures were
utilized (164-168). Furthermore, we carefully assessed behavior during the intervening cleared
period (susceptibility period for infection re-acquisition). The study also had several limitations
that may have affected our results. We did not have information regarding HPV infection status
of participants prior to the study start, therefore it is likely that participants may have had
acquired and cleared infections prior to entering the study. Obtaining data for prior HPV DNA
status is challenging as significant cost and resources are required to obtain this information,
especially among men who were sexually active for a long time. There is also a possibility of
existing latent infection prior to study start or during the follow-up being detected as another
61

infection (163, 169-172). Latency of HPV is proposed based on the animal model whereby HPV
is retained in a latent state in the basal epithelial stem cell pool (163). Current HPV DNA
detection methods may not be sensitive enough to detect low viral load of latent infections (169171) and re-activation of latent infection is less likely in immune competent subjects (as in the
HIM study). Future studies are needed to further elucidate the latency of HPV infections in men
and women.
Misclassification of HPV infection status is also a possibility. Low viral load and long
period of time between the initial infection and assessment of HPV DNA may lead to
misclassification of HPV infection status. However, such misclassification should play a very
minor role in analyses, considering the robust methods used for HPV DNA detection (164-168).
We did not have a sufficient number of recurrent infections to adequately power our individual
type-specific analyses, especially for less common HPV types (e.g. HPV 11, 31, 33). We
attempted to address this issue in our grouped analyses of all nine HPV types. Furthermore,
subjects excluded from the analysis did not differ significantly from study participants for sexual
behavior and other important demographic variables.
In conclusion, men are susceptible to genital HPV infection recurrence, with up to 31% of
prevalent and 20% of incident infections recurring over time. Recurrence of HPV infection
among men may be influenced by high-risk sexual behavior; including higher numbers of new
sexual partners and lifetime sexual partners. Given the complexity of analyzing recurrence of
HPV infections, future studies are needed to further understand the role of HPV recurrence in the
etiology of HPV associated diseases.
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Study Population
(n= 4,123)

HPV DNAnegative
men
throughout
the followup

Men with incident
or prevalent
infections that
persisted
throughout the
study period

Men with
incident or
prevalent
infections who
dropped out
before
clearance

Incident infections
- Transient infection: One time
DNA detection
e.g. 0100
- Persistent infection
e.g. 01100 or 010100

Prevalent infections at
baseline
-Transient infection: One time
prevalent infection at baseline
e.g. 100
- Prevalent persistent infection
e.g. 1100 or 10100

Excluded

Non-recurrent
(cleared)

Recurrent
infection

Non-recurrent
(cleared)

Recurrent
infection

- Transient
e.g. 001000
- Persistent:
e.g. 01100000

- Incident:
e.g. 001001
- Persistent:
e.g. 0110001

- Transient:
e.g. 1000
- Persistent:
e.g. 11000

- Prevalent:
e.g. 1001
- Persistent:
e.g. 110001

Figure 3.1: Outline for tracking recurrent infections
63

Footnote: In examples, 0 = HPV DNA-negative status, 1 = HPV DNA-positive status
Total numbers of excluded subjects according to HPV types were: HPV6 = 621, HPV11 =171, HPV16 = 762,
HPV18 = 300, HPV31 = 226, HPV33 = 76, HPV45 = 268, HPV52 = 486, and HPV58 = 292.
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35
30
25
20
Incident recurrent
15

Prevalent recurrent

10
5
0
HPV6 HPV11 HPV16 HPV18 HPV31 HPV33 HPV45 HPV52 HPV58

Figure 3.2: Proportion of recurrence infection among total prevalent and incident
infections for HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58 among men in USA, Brazil and
Mexico in the HIM study.
Footnotes:
Abbreviation: HPV, human papillomavirus.
Incident Recurrent: Incident infections (either transient or persistent) that cleared (2 successive negative
DNA results) and then recurred during the median follow-up time of 48 months.
Prevalent Recurrent: Prevalent infections (either transient or persistent) that cleared (2 successive
negative DNA results) and then recurred during the median follow-up time of 48 months
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Table 3.1a: Proportion of recurrent infections among men with a prior prevalent HPV 6,
11, 16, 18, 31, 33, 45, 52 and 58 infections.
HPV types

Total
prevalent
infections

Transient Prevalenta infections

Persistent Prevalentb infections

Recurrentc /
Total
transient
infections

Proportion (%)

Recurrentd /
Total persistent
infections

Proportions
(%)

HPV 6

260

29/146

19.86

25/114

21.93

HPV 11

58

1/26

3.85

6/32

18.75

HPV 16

282

26/133

19.55

35/149

23.50

HPV 18

103

10/57

17.54

9/46

19.57

HPV 31

81

8/44

18.18

4/37

10.81

HPV 33

25

1/13

7.69

2/12

16.67

HPV 45

86

11/48

22.92

14/38

36.84

HPV 52

161

29/93

31.18

22/68

32.35

HPV 58

101

9/42

21.43

12/59

20.34

Footnotes:
Abbreviation: HPV, human papillomavirus.
a

Transient prevalent infection: A prevalent infection that was detected at only one time point

b

Persistent prevalent infection: Persistence of prevalent infection for duration of 6 months or more, that
cleared at some point during follow-up.
c

Transient prevalent recurrent: Prevalent infections that cleared (2 successive negative DNA results)
and then recurred during the follow-up period
d

Prevalent persistent recurrent: Persistent prevalent infections that cleared (2 successive negative DNA
results) and then recurred during the median follow-up time of 48 months.
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Table 3.1b: Proportion of recurrent infections among men with a prior incident HPV 6,
11, 16, 18, 31, 33, 45, 52 and 58 infections.

HPV types

Total incident
infections

Transient incidenta infections

Incident persistentb infections

Recurrentc /
Total incident
infections

Proportion
s (%)

Recurrentd /
Total persistent
infections

Proportions (%)

HPV 6

211

15/164

9.15

6/47

12.77

HPV 11

79

0/60

0.00

5/19

26.32

HPV 16

249

22/195

11.28

4/54

7.41

HPV 18

121

11/87

12.64

6/34

17.65

HPV 31

90

6/66

9.09

3/24

12.50

HPV 33

39

2/33

6.06

0/6

0.00

HPV 45

121

10/99

10.10

3/22

13.64

HPV 52

204

22/151

14.57

13/53

24.53

HPV 58

104

14/71

19.72

3/33

9.09

Footnotes:
Abbreviation: HPV, human papillomavirus.
a

Transient incident: An incident infection that was detected at only one time point

b

Incident persistent infection: An incident infection that had an observed duration of 6 month or more.

c

Transient incident recurrent: incident infections that cleared (2 successive negative results) and then
recurred during the follow-up period.
d

Incident persistent recurrent: Persistent incident infections that cleared (2 successive negative results)
and then recurred during the median follow-up time of 48 months.
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Table 3.2a - Factors associated with type specific recurrence of prior prevalenta HPV infections (HPV 6, 16 and 18), with
sexual behaviors assessed during intervening cleared periodb
Behavior variables

HPV 6
Nonrecurrent

Recurrent

HPV 16
p-value

c

Nonrecurrent

Recurrent

HPV 18
p-value

c

Nonrecurrent

Recurrent

p-valuec

Smoking
Never

124 (79.0)

33 (21.0)

Former

18 (78.3)

Current

0.9734

138 (78.4)

38 (21.6)

5 (21.7)

14 (70.0)

63 (80.8)

15 (19.2)

0-<0.5 drinks/day

84 (84.8)

15 (15.2)

0.5-<1.5 drinks/day

39 (73.6)

≥1.5 drinks/day

0.6922

49 (80.3)

12 (19.7)

6 (30.0)

8 (80.0)

2 (20.0)

65 (79.3)

17 (20.7)

26 (83.9)

5 (16.1)

85 (75.9)

27 (24.1)

22 (75.9)

7 (24.1)

14 (26.4)

44 (77.2)

13 (22.8)

24 (80.0)

6 (20.0)

80 (76.9)

24 (23.1)

85 (80.2)

21 (19.8)

36 (87.8)

5 (12.2)

0-1 partners

28 (80.0)

7 (20.0)

37 (74.0)

13 (26.0)

9 (81.8)

2 (18.2)

2-12 partners

82 (83.7)

16 (16.3)

69 (79.3)

18 (20.7)

33 (84.6)

6 (15.4)

>12 partners

82 (72.6)

31 (27.4)

100 (77.5)

29 (22.5)

31 (77.5)

9 (22.5)

91 (79.8)
39 (88.6)
26 (56.5)

23 (20.2)
5 (11.4)
20 (43.5)

108 (77.1)
31 (75.6)
57 (81.4)

32 (22.9)
10 (24.4)
13 (18.6)

45 (84.9)
8 (72.7)
19 (73.1)

8 (15.1)
3 (27.3)
7 (26.9)

0.9330

Alcohol use
0.1820

0.7593

0.4655

Lifetime female
sexual partners

No. of new female
sexual partners in
previous 6-12
monthse
0 partners
1 partners
≥2 partners

0.1523

0.0007
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0.7865

0.7582

0.8172

0.3684

Table 3.2a (Continued)
Behavior variables

Nonrecurrent

HPV 6
Recurrent

p-valuec

Nonrecurrent

HPV 16
Recurrent

p-valuec

Nonrecurrent

HPV 18
Recurrent

p-valuec

Frequency of sexual
intercourse with
female partners in
last 6-12 months
0-5

43 (78.2)

12 (21.8)

6-30

44 (78.6)

>30

0.9812

50 (70.4)

21 (29.6)

21 (84.0)

4 (16.0)

12 (21.4)

58 (87.9)

8 (12.1)

15 (78.9)

4 (21.1)

102 (77.3)

30 (22.7)

101 (76.5)

31 (23.5)

40 (81.6)

9 (18.4)

155 (77.1)

46 (22.9)

177 (79.0)

47 (21.0)

63 (77.8)

18 (22.2)

30 (85.7)

5 (14.3)

21 (77.8)

6 (22.2)

13 (100.0)

0 (0.0)

0 partners

160 (77.7)

46 (22.3)

181 (78.7)

49 (21.3)

68 (79.1)

18 (20.9)

≥ 1 partners

24 (80.0)

6 (20.0)

18 (81.8)

4 (18.2)

10 (100.0)

0 (0.0)

0.0452

0.9357

Lifetime male sexual
partners
None
≥1 partners

0.2740

1.0000

0.1201

No. of new male
sexual partners in
previous 6-12 months
0.8183

0.7920

0.1986

Footnotes:
Abbreviations: HPV, human papilloma virus, NA- Not applicable.
a – Prevalent infections included prevalent infections and prevalent infections that persisted for a duration of 6 months or more.
b – Intervening cleared period was defined as time period after clearance (two successive negative DNA detections) for the last DNA positive result for the type
specific incident HPV infection. For recurrent infection it was the visit when recurrence was observed (behavior was inquired for previous 6 months) and one
visit prior to recurrence (incident was cleared during this time and they were susceptible to recurrence).
c - p-values for categorical variables were calculated using the chi-square test with Monte Carlo estimation of exact p-values, α = 0.05. p- value represents global
value for overall difference between non-recurrent and recurrent infections.
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Table 3.2b - Factors associated with type specific recurrence of prior prevalenta HPV infections (HPV 6, 16 and 18), with sexual
behaviors assessed during intervening cleared periodb
HPV 31

HPV 45

HPV 52

HPV 58

Behavior variables
Non-recurrent

Recurrent

pc

Non-recurrent

Recurrent

pc

Non-recurrent

Recurrent

pc

Non-recurrent

Recurrent

pc

1.000

40 (71.4)

16 (28.6)

0.500

57 (62.0)

35 (38.0)

0.109

44 (77.2)

13 (22.8)

0.087

Smoking
Never

47 (85.5)

8 (14.5)

Former

2 (100.0)

0 (0.0)

7 (87.5)

1 (12.5)

14 (77.8)

4 (22.2)

3 (50.0)

3 (50.0)

Current

20 (83.3)

4 (16.7)

14 (63.6)

8 (36.4)

38 (77.6)

11 (22.4)

33 (86.8)

5 (13.2)

0-<0.5 drinks/day

28 (90.3)

3 (9.7)

28 (80.0)

7 (20.0)

45 (71.4)

18 (28.6)

28 (65.1)

15 (34.9)

0.5-<1.5 drinks/day

7 (70.0)

3 (30.0)

10 (62.5)

6 (37.5)

19 (67.9)

9 (32.1)

19 (90.5)

2 (9.5)

≥1.5 drinks/day

31 (83.8)

6 (16.2)

21 (65.6)

11 (34.4)

42 (64.6)

23 (35.4)

33 (89.2)

4 (10.8)

0-1 partners

5 (100.0)

0 (0.0)

6 (75.0)

2 (25.0)

14 (82.4)

3 (17.6)

11 (84.6)

2 (15.4)

2-12 partners

22 (75.9)

7 (24.1)

20 (76.9)

6 (23.1)

37 (72.5)

14 (27.5)

26 (81.3)

6 (18.8)

>12 partners

38 (88.4)

5 (11.6)

31 (75.6)

10 (24.4)

52 (62.7)

31 (37.3)

40 (80.0)

10 (20.0)

0 partners

30 (88.2)

4 (11.8)

30 (75.0)

10 (25.0)

53 (72.6)

20 (27.4)

45 (83.3)

9 (16.7)

1 partners

8 (61.5)

5 (38.5)

9 (81.8)

2 (18.2)

12 (50.0)

12 (50.0)

15 (78.9)

4 (21.1)

≥2 partners

23 (92.0)

2 (8.0)

15 (62.5)

9 (37.5)

22 (61.1)

14 (38.9)

13 (61.9)

8 (38.1)

Alcohol use
0.283

0.313

0.725

0.010

Lifetime female sexual
partners
0.167

1.000

0.206

1.000

No. of new female sexual
partners in previous 6-12
monthse
0.032
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0.458

0.108

0.149

Table3.2b (Continued)
Behavior variables

HPV 31

HPV 45
c

HPV 52
c

HPV 58
c

Non-recurrent

Recurrent

p

Non-recurrent

Recurrent

p

Non-recurrent

Recurrent

p

Non-recurrent

Recurrent

pc

0-5

9 (75.0)

3 (25.0)

0.649

14 (82.4)

3 (17.6)

0.577

25 (71.4)

10 (28.6)

0.103

18 (69.2)

8 (30.8)

0.204

6-30

11 (84.6)

2 (15.4)

14 (82.4)

3 (17.6)

28 (82.4)

6 (17.6)

18 (78.3)

5 (21.7)

>30

45 (86.5)

7 (13.5)

28 (70.0)

12 (30.0)

53 (63.1)

31 (36.9)

43 (86.0)

7 (14.0)

None

63 (85.1)

11 (14.9)

47 (70.1)

20 (29.9)

86 (65.2)

46 (34.8)

67 (82.7)

14 (17.3)

≥1 partners

2 (66.7)

1 (33.3)

9 (7.05)

3 (25.0)

14 (82.4)

3 (17.6)

6 (60.0)

4 (40.0)

None

63 (85.1)

11 (14.9)

49 (69.0)

22 (31.0)

88 (64.7)

48 (35.3)

68 (82.9)

14 (17.1)

≥1 partners

3 (75.0)

1 (25.0)

7 (87.5)

1 (12.5)

11 (84.6)

2 (15.4)

6 (60.0)

4 (40.0)

Frequency of sexual
intercourse with female
partners in last 6-12
months

Lifetime male sexual
partners
0.403

1.000

0.182

0.108

No. of new male sexual
partners in previous 612 monthse
1.000

0.429

0.227

0.101

Footnotes:
Abbreviations: HPV, human papilloma virus.
a – Prevalent infections included prevalent infections and prevalent infections that persisted for a duration of 6 months or more.
b – Intervening cleared period was defined as time period after clearance (two successive negative DNA detections) for the last DNA positive result for the type
specific incident HPV infection. For recurrent infection it was the visit when recurrence was observed (behavior was inquired for previous 6 months) and one
visit prior to recurrence (incident was cleared during this time and they were susceptible to recurrence).
c - p-values for categorical variables were calculated using the chi-square test with Monte Carlo estimation of exact p-values, α = 0.05. p- value represents global
value for overall difference between non-recurrent and recurrent infections.
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Table 3.3a- Factors associated with type specific recurrence of prior incidenta HPV infections (HPV 6, 16 and
18), with sexual behaviors assessed during intervening cleared periodb
Behavior variables

HPV 6
Nonrecurrent

Recurrent

HPV 16
p-value

c

HPV 18

Nonrecurrent

Recurrent

p-value

160 (92.0)

14 (8.0)

0.0636

c

Nonrecurrent

Recurrent

p-valuec

69 (86.3)

11 (13.8)

0.8385

Smoking
Never

133 (90.5)

14 (9.5)

0.7573

Former

4 (80.0)

1 (20.0)

11 (91.7)

1 (8.3)

2 (100.0)

0 (0.0)

Current

51 (91.1)

5 (8.9)

48 (81.4)

11 (18.6)

31 (83.8)

6 (16.2)

0-<0.5 drinks/day

84 (94.4)

5 (5.6)

90 (90.0)

10 (10.0)

44 (86.3)

7 (13.7)

0.5-<1.5 drinks/day

35 (83.3)

7 (16.7)

48 (88.9)

6 (11.1)

18 (85.7)

3 (14.3)

≥1.5 drinks/day

68 (88.3)

9 (11.7)

81 (89)

10 (11)

41 (85.4)

7 (14.6)

0-1 partners

25 (92.6)

2 (7.4)

30 (88.2)

4 (11.8)

5 (100.0)

0 (0.0)

2-12 partners

68 (90.7)

7 (9.3)

74 (86.0)

12 (14.0)

27 (84.4)

5 (15.6)

>12 partners

82 (89.1)

10 (10.9)

100 (92.6)

8 (7.4)

61 (87.1)

9 (12.9)

104 (92.0)
34 (87.2)
40 (87.0)

9 (8.0)
5 (12.8)
6 (13.0)

117 (88.0)
38 (86.4)
60 (93.8)

16 (12.0)
6 (13.6)
4 (6.3)

39 (84.8)
14 (93.3)
47 (87.0)

7 (15.2)
1 (6.7)
7 (13.0)

Alcohol use
0.1195

1.0000

1.0000

Lifetime female
sexual partners

No. of new female
sexual partners in
previous 6-12
monthse
0 partners
1 partners
≥2 partners

0.8472

0.5831
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0.3456

0.4007

0.6230

0.7480

Table 3.3a (Continued)
HPV 6

Behavior variables
Nonrecurrent

Recurrent

HPV 16
p-valuec

HPV 18

Nonrecurrent

Recurrent

p-valuec

Nonrecurrent

Recurrent

p-valuec

51 (89.5)

6 (10.5)

1.0000

15 (83.3)

3 (16.7)

0.1587

Frequency of sexual
intercourse with
female partners in
last 6-12 months
0-5

40 (93.0)

3 (7.0)

0.7489

6-30

45 (88.2)

6 (11.8)

43 (89.6)

5 (10.4)

16 (76.2)

5 (23.8)

>30

91 (89.2)

11 (10.8)

114 (89.1)

14 (10.9)

65 (91.5)

6 (8.5)

None

155 (90.6)

16 (9.4)

179 (90.9)

18 (9.1)

86 (87.8)

12 (12.2)

≥1 partners

20 (83.3)

4 (16.7)

20 (90.9)

2 (9.1)

11 (73.3)

4 (26.7)

0 partners

158 (90.8)

16 (9.2)

187 (91.2)

18 (8.8)

88 (86.3)

14 (13.7)

≥ 1 partners

18 (81.8)

4 (18.2)

15 (71.4)

6 (28.6)

11 (78.6)

3 (21.4)

Lifetime male sexual
partners
0.2851

1.0000

0.2276

No. of new male
sexual partners in
previous 6-12 months
0.2543

0.0111

0.6939

Footnotes:
Abbreviations: HPV, human papilloma virus.
a – Incident infections include incident infections and incident infections that persisted for a duration of 6 months or more.
b – Intervening cleared period was defined as time period after clearance (two successive negative DNA detections) for the last DNA positive result for
the type specific incident HPV infection. For recurrent infection it was the visit when recurrence was observed (behavior was inquired for previous 6
months) and one visit prior to recurrence (incident was cleared during this time and they were susceptible to recurrence).
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c - p-values for categorical variables were calculated using the chi-square test with Monte Carlo estimation of exact p-values, α = 0.05. p- value
represents global value for overall difference between non-recurrent and recurrent infections.
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Table 3.3b- Factors associated with type specific recurrence of prior incidenta HPV infections (HPV 31, 45, 52 and 58), with
sexual behaviors assessed during intervening cleared periodb
HPV 31

HPV 45

HPV 52

HPV 58

Behavior variables
Nonrecurrent

Recurrent

p-valuec

Nonrecurrent

Recurrent

pvaluec

Nonrecurrent

Recurrent

pvaluec

Nonrecurrent

Recurrent

pvaluec

1.0000

105 (78.9)

28 (21.1)

0.0488

54 (83.1)

11 (16.9)

0.6941

Smoking

Never

48 (90.6)

5 (9.4)

1.0000 78 (88.6)

10 (11.4)

Former

7 (87.5)

1 (12.5)

4 (100.0)

0 (0.0)

8 (72.7)

3 (27.3)

5 (100.0)

0 (0.0)

Current

24 (88.9)

3 (11.1)

26 (89.7)

3 (10.3)

53 (93.0)

4 (7.0)

26 (81.3)

6 (18.8)

0-<0.5 drinks/day

36 (90.0)

4 (10.0)

1.0000 55 (90.2)

60 (84.5)

11 (15.5)

33 (78.6)

9 (21.4)

0.5-<1.5 drinks/day

20 (90.9)

2 (9.1)

16 (100)

0 (0)

39 (81.3)

9 (18.8)

15 (88.2)

2 (11.8)

≥1.5 drinks/day

24 (88.9)

3 (11.1)

34 (82.9)

7 (17.1)

66 (81.5)

15 (18.5)

39 (86.7)

6 (13.3)

0-1 partners

14 (87.5)

2 (12.5)

0.6604 17 (94.4)

17 (70.8)

7 (29.2)

10 (90.9)

1 (9.1)

2-12 partners

23 (95.8)

1 (4.2)

29 (87.9)

4 (12.1)

51 (89.5)

6 (10.5)

23 (85.2)

4 (14.8)

>12 partners

38 (90.5)

4 (9.5)

46 (86.8)

7 (13.2)

84 (81.6)

19 (18.4)

45 (83.3)

9 (16.7)

0 partners

43 (89.6)

5 (10.4)

0.4763 48 (85.7)

8 (14.3)

75 (80.6)

18 (19.4)

40 (85.1)

7 (14.9)

1 partners

11 (100.0)

0 (0.0)

20 (95.2)

1 (4.8)

27 (84.4)

5 (15.6)

13 (76.5)

4 (23.5)

≥2 partners

24 (85.7)

4 (14.3)

30 (90.9)

3 (9.1)

53 (82.8)

11 (17.2)

32 (86.5)

5 (13.5)

Alcohol use

6 (9.8)

0.1893

0.8899

0.5321

Lifetime female
sexual partners
1 (5.6)

0.6607

0.1218

0.9234

No. of new female
sexual partners in
previous 6-12
monthse
0.4800

75

0.9020

0.6666

Table 3.3b (Continued)
Behavior variables

HPV 31
Nonrecurrent

Recurrent

HPV 45
p-value

c

Nonrecurrent

HPV 52

Recurrent

pvaluec

Nonrecurrent

HPV 58

Recurrent

pvaluec

Nonrecurrent

Recurrent

pvaluec

32 (78.0)

9 (22.0)

0.6089

18 (94.7)

1 (5.3)

0.0886

Frequency of sexual
intercourse with
female partners in
last 6-12 months
0-5

20 (83.3)

4 (16.7)

0.5339 32 (91.4)

3 (8.6)

6-30

14 (93.3)

>30

0.6701

1 (6.7)

20 (90.9)

2 (9.1)

44 (86.3)

7 (13.7)

21 (91.3)

2 (8.7)

40 (93.0)

3 (7.0)

40 (85.1)

7 (14.9)

78 (82.1)

17 (17.9)

42 (76.4)

13 (23.6)

None

58 (92.1)

5 (7.9)

0.3575 68 (88.3)

9 (11.7)

124 (82.1)

27 (17.9)

72 (83.7)

14 (16.3)

≥1 partners

13 (81.3)

3 (18.8)

25 (89.3)

3 (10.7)

7 (77.8)

2 (22.2)

0 partners

59 (92.2)

5 (7.8)

129 (82.7)

27 (17.3)

71 (83.5)

14 (16.5)

≥ 1 partners

13 (81.3)

3 (18.8)

26 (92.9)

2 (7.1)

9 (81.8)

2 (18.2)

Lifetime male
sexual partners

31 (93.9)

0.5014

2 (6.1)

0.4253

1.0000

No. of new male
sexual partners in
previous 6-12
months
0.3396 73 (89.0)

9 (11.0)

27 (90.0)

3 (10.0)

1.0000

0.2566

1.0000

Footnotes:
Abbreviations: HPV, human papilloma virus.
a – Incident infections include incident infections and incident infections that persisted for a duration of 6 months or more.
b – Intervening cleared period was defined as time period after clearance (two successive negative DNA detections) for the last DNA positive result for
the type specific incident HPV infection. For recurrent infection it was the visit when recurrence was observed (behavior was inquired for previous 6
months) and one visit prior to recurrence (incident was cleared during this time and they were susceptible to recurrence).
c - p-values for categorical variables were calculated using the chi-square test with Monte Carlo estimation of exact p-values, α = 0.05. p- value
represents global value for overall difference between non-recurrent and recurrent infection

76

100
90
80
70
60
50
Non-Recurrent infections

40

Recurrent infections

30
20

10
0
Incident infection for Prevalent infection Prevalent of one type
any nine type HPVs for any nine type
and Incident of
HPVs
another type

Figure 3.3: Proportions of incident and prevalent infection for nine vaccine type HPVs (6, 11, 16, 18, 31, 33, 45, 52, and 58)
according to recurrence status in grouped analyses.
Footnotes:
Abbreviation: HPV, human papillomavirus
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Table 3.4- Demographic characteristics comparing incident infections that recur or do not recur and prevalent infections that recur or do
not recur for any of the 9 type of HPVs (HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58) among men in the HIM study.
Incident infections
Demographic variables

Prevalent infections

Non-Recurrent
N (%)

Recurrent
N (%)

p-valuea

Non-Recurrent
N (%)

Recurrent
N (%)

p-valuea

United States

144 (84.2)

27 (15.8)

0.1383

139 (74.7)

47 (25.3)

0.7281

Brazil

246 (85.4)

42 (14.6)

190 (74.2)

Mexico

160 (90.9)

16 (9.1)

18-30

255 (87.0)

38 (13.0)

31-44

215 (87.0)

45-73

Prevalent infection for one type and incident
for another type
Non-Recurrent N Recurrent N
p-valuea
(%)
(%)

Country
30 (51.7)

28 (48.3)

66 (25.8)

83 (56.1)

65 (43.9)

154 (77.4)

45 (22.6)

36 (65.5)

19 (34.5)

243 (78.9)

65 (21.1)

90 (58.8)

63 (41.2)

32 (13.0)

188 (73.2)

69 (26.8)

46 (54.8)

38 (45.2)

80 (84.2)

15 (15.8)

52 (68.4)

24 (31.6)

13 (54.2)

11 (45.8)

Single

240 (84.8)

43 (15.2)

222 (77.6)

64 (22.4)

84 (57.5)

62 (42.5)

Married/Cohabiting

307 (88.0)

42 (12.0)

209 (73.1)

77 (26.9)

50 (58.1)

36 (41.9)

50 (89.3)

6 (10.7)

49 (75.4)

16 (24.6)

14 (50.0)

14 (50.0)

Whites

234 (82.4)

50 (17.6)

227 (73.2)

83 (26.8)

72 (56.7)

55 (43.3)

African-Americans

112 (88.9)

14 (11.1)

70 (77.8)

20 (22.2)

35 (56.5)

27 (43.5)

Asians/Pacific islander

11 (91.7)

1 (8.3)

7 (63.6)

4 (36.4)

2 (66.7)

1 (33.3)

Mixed race/Othersb

186 (91.2)

18 (8.8)

172 (78.2)

48 (21.8)

38 (59.4)

26 (40.6)

0.3084

Age
0.7751

0.0892

0.8225

Marital status

Divorced/Separated/Widowed

0.4867

0.4352

0.7864

Race
0.0359

78

0.4273

0.9721

Table 3.4 (Continued)
Demographic variables

Incident infections

Prevalent infections

Non-Recurrent
N (%)

Recurrent
N (%)

p-valuea

Non-Recurrent
N (%)

Recurrent
N (%)

p-valuea

≤ 12 years

273 (86.4)

43 (13.6)

0.7707

230 (73.7)

82 (26.3)

0.1634

13-15 years

141 (85.5)

24 (14.5)

112 (81.8)

≥16 years

135 (88.2)

18 (11.8)

Non-drinkers

174 (86.6)

27 (13.4)

<0.5 drinks/day

157 (86.3)

0.5-2 drinks/day

Prevalent infection for one type and incident
for another type
Non-Recurrent N Recurrent N
p-valuea
(%)
(%)

Education
78 (58.6)

55 (41.4)

25 (18.2)

30 (54.5)

25 (45.5)

140 (74.1)

49 (25.9)

40 (55.6)

32 (44.4)

204 (79.7)

52 (20.3)

38 (64.4)

21 (35.6)

25 (13.7)

114 (71.3)

46 (28.8)

38 (50.0)

38 (50.0)

219 (86.9)

33 (13.1)

165 (73.3)

60 (26.7)

73 (57.9)

53 (42.1)

Never

352 (85.4)

60 (14.6)

319 (76.3)

99 (23.7)

82 (54.3)

69 (45.7)

Former smoker

30 (93.8)

2 (6.3)

34 (75.6)

11 (24.4)

8 (57.1)

6 (42.9)

Current smoker

168 (88.0)

23 (12.0)

130 (73.0)

48 (27.0)

59 (61.5)

37 (38.5)

No

357 (87.7)

50 (12.3)

320 (75.1)

106 (24.9)

109 (62.6)

65 (37.4)

Yes

193 (84.6)

35 (15.4)

163 (75.8)

52 (24.2)

40 (46.0)

47 (54.0)

MSW

380 (86.4)

60 (13.6)

340 (74.7)

115 (25.3)

105 (57.7)

77 (42.3)

MSM

29 (82.9)

6 (17.1)

20 (76.9)

6 (23.1)

9 (75.0)

3 (25.0)

MSWM

70 (85.4)

12 (14.6)

69 (78.4)

19 (21.6)

21 (51.2)

20 (48.8)

0.8409

Alcohol use*
0.9887

0.1014

0.2436

Cigarette smoking*
0.3288

0.6832

0.5879

Circumcision
0.3357

0.9233

0.0111

Sexual orientation
0.8233

79

0.7534

0.3327

Table 3.4 (Continued)
Incident infections

Prevalent infections

Non-Recurrent
N (%)

Recurrent
N (%)

p-valuea

Non-Recurrent
N (%)

Recurrent
N (%)

p-valuea

0-1 partners

66 (82.5)

14 (17.5)

0.4199

68 (81.0)

16 (19.0)

0.3773

2-12 partners

221 (88)

30 (12)

187 (76.0)

>12 partners

253 (87.2)

37 (12.8)

0 partners

210 (84.0)

40 (16.0)

1 partners

205 (88.0)

≥2 partners

Demographic variables

Prevalent infection for one type and incident
for another type
Non-Recurrent N Recurrent N
p-valuea
(%)
(%)

Lifetime female sexual
partners*
13 (65.0)

7 (35.0)

59 (24.0)

48 (64.0)

27 (36.0)

215 (73.6)

77 (26.4)

82 (52.6)

74 (47.4)

211 (77.0)

63 (23.0)

42 (61.8)

26 (38.2)

28 (12.0)

150 (73.2)

55 (26.8)

54 (56.8)

41 (43.2)

131 (89.7)

15 (10.3)

94 (71.8)

37 (28.2)

50 (54.3)

42 (45.7)

None

466 (88.3)

62 (11.7)

392 (74.0)

138 (26.0)

119 (56.9)

90 (43.1)

1-12

34 (87.2)

5 (12.8)

31 (79.5)

8 (20.5)

15 (57.7)

11 (42.3)

>12 partners

35 (72.9)

13 (27.1)

30 (83.3)

6 (16.7)

11 (52.4)

10 (47.6)

0 partners

479 (88.4)

63 (11.6)

403 (74.6)

137 (25.4)

117 (56.8)

89 (43.2)

1 partners

22 (81.5)

5 (18.5)

30 (73.2)

11 (26.8)

28 (54.9)

23 (45.1)

≥2 partners

36 (73.5)

13 (26.5)

22 (78.6)

6 (21.4)

0 (0.00)

0 (0.00)

0.1971

No. of new female sexual
partners*
0.2127

0.4468

0.6439

Lifetime male sexual partners*
0.0116

0.3708

0.9426

No. of new male partners*
0.0111

80

0.8566

0.8745

Footnotes:
Abbreviations: HPV, human papilloma virus; MSM, men who have sex with men; MSW, men who have sex with women; MSWM, men who have
sex with women and men
* These variables are based on overall behavior pattern of an individual during the 4 year follow-up time. An individual with most frequent
behavior (e.g. 0-1 lifetime partners) during the entire follow-up was assigned in that particular category. There will be multiple intervening time
period (susceptibility period for recurrence) for multiple HPV type infections and analysis based on these different intervals is not possible here.
a - p-values for categorical variables were calculated using the chi-square test with Monte Carlo estimation of p-values, α = 0.05. p- value
represents global value for overall difference between incident and recurrent infections.
b - Includes mixed race, American Indians, Alaska natives, Native Hawaiians or other races
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Table 3.5 – Odds ratio and 95% confidence intervals for recurrent infections by demographic characteristics for
any of the 9 type of HPVs (HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58) among men in the HIM study
Incident infections
Variables*

Strata

Prevalent infections
a

Prevalent of one type and incident of another type

Crude OR and
95% CI

Adjusted OR and
95% CI

Crude OR and
95% CI

Adjusted OR and
95% CI

Crude OR and
95% CI

Adjusted OR and 95% CI

1.00 (Ref.)

1.00 (Ref.)

1.00 (Ref.)

1.00 (Ref.)

Alcohol use
0-<0.5

a

1.00 (Ref.)

1.00 (Ref.)

1.58 (1.00, 2.50)

1.59 (1.01, 2.53)

c

1.81 (0.90, 3.63)

1.97 (0.96, 4.06)d

0.5-<1.5

1.03 (0.57 1.84)

1.01 (0.55, 1.91)

≥1.5

0.97 (0.56, 1.68)

0.90 (0.50, 1.60)a

1.43 (0.93, 2.18)

1.40 (0.92, 2.15)c

1.31 (0.69, 2.49)

1.22 (0.63, 2.36)d

Never

1.00 (Ref.)

1.00 (Ref.)

1.00 (Ref.)

1.00 (Ref.)

Cigarette smoking

a

1.00 (Ref.)

1.00 (Ref.)

1.04 (0.51, 2.13)

1.06 (0.52, 2.17)

c

0.88 (0.30, 2.69)

0.89 (0.29, 2.76)d

Former

0.39 (0.09, 1.68)

0.43 (0.10, 1.87)

Current

0.80 (0.48, 1.34)

0.73 (0.42, 1.30)a

1.19 (0.80, 1.78)

1.21 (0.81, 1.81)c

0.75 (0.44, 1.26)

0.80 (0.46, 1.39)d

1.00 (Ref.)

1.00 (Ref.)

1.00 (Ref.)

1.00 (Ref.)

Lifetime female
sexual partners
0-1 partners

a

1.00 (Ref.)

1.00 (Ref.)

1.34 (0.72, 2.49)

1.39 (0.74, 2.59)

c

1.05 (0.37, 2.93)

1.13 (0.39, 3.25)d

2-12 partners

0.64 (0.32, 1.28)

0.73 (0.32, 1.66)

>12 partners

0.69 (0.35, 1.35)

0.85 (0.38, 1.92)a

1.52 (0.83, 2.78)

1.50 (0.82, 2.75)c

1.68 (0.64, 4.43)

1.68 (0.63, 4.44)d

1.00 (Ref.)

1.00 (Ref.)

1.00 (Ref.)

1.00 (Ref.)

No. of new female
sexual partners
0 partners

a

1.00 (Ref.)

1.00 (Ref.)

1.22 (0.80, 1.86)

1.23 (0.81, 1.87)

c

1.23 (0.65, 2.32)

1.14 (0.60, 2.19)d

1 partners

0.72 (0.43, 1.21)

0.91 (0.51, 1.62)

≥2 partners

0.60 (0.32, 1.13)

0.69 (0.35, 1.35)a

1.32 (0.82, 2.12)

1.29 (0.79, 2.08)c

1.36 (0.72, 2.57)

1.19 (0.61, 2.33)d

0-5

1.00 (Ref.)

1.00 (Ref.)

1.00 (Ref.)

1.00 (Ref.)

1.00 (Ref.)

1.00 (Ref.)

6-30

0.58 (0.31, 1.09)

0.93 (0.39, 2.23)a

1.22 (0.73, 2.06)

1.24 (0.74, 2.10)c

1.01 (0.48, 2.14)

1.03 (0.47, 2.21)d

>30

0.72 (0.40, 1.31)

1.27 (0.53, 3.04)a

1.12 (0.67, 1.86)

1.12 (0.68, 1.87)c

1.06 (0.54, 2.10)

0.99 (0.49, 1.98)d

Frequency of
intercourse with
female partners
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Table 3.5 (Continued)
Incident infections
Variables*

Strata

Prevalent infections
a

Prevalent of one type and incident of another type

Crude OR and
95% CI

Adjusted OR and
95% CI

Crude OR and
95% CI

Adjusted OR and
95% CI

Crude OR and
95% CI

Adjusted OR and 95% CI

1.00 (Ref.)

1.00 (Ref.)

1.00 (Ref.)

1.00 (Ref.)

Lifetime male
sexual partners
None

b

1.00 (Ref.)

1.00 (Ref.)

0.73 (0.33, 1.63)

0.71 (0.32, 1.60)

c

0.97 (0.43, 2.21)

1.12 (0.48, 2.62)d

1-12 partners

1.11 (0.42, 2.93)

1.02 (0.38, 2.73)

>12 partners

2.79 (1.40, 5.56)

2.40 (1.19, 4.84)b

0.57 (0.23, 1.39)

0.53 (0.21, 1.32)c

1.20 (0.49, 2.95)

1.26 (0.50, 3.20)d

0 partners

1.00 (Ref.)

1.00 (Ref.)

1.00 (Ref.)

1.00 (Ref.)

1.00 (Ref.)

1.00 (Ref.)

1 partners

1.73 (0.63, 4.73)

1.19 (0.39, 3.61)b

1.08 (0.53, 2.21)

1.04 (0.50, 2.15)c

1.08 (0.58, 2.00)

1.18 (0.62, 2.26)d

≥2 partners

2.75 (1.38, 5.46)

2.35 (1.16, 4.74)b

0.80 (0.32, 2.02)

0.76 (0.30, 1.94)c

0.00 (NE)

0.00 (NE)

No. of new male
sexual partners

Footnotes: HPV- Human papillomavirus, OR-Odds ratio, NE-Not estimable
* This variables are based on overall behavior pattern of an individual during the 4 year follow-up time. An individual with most frequent
behavior (e.g. 0-1 lifetime partners) during the entire follow-up was assigned in that particular category. There will be multiple intervening
time period (susceptibility period for recurrence) for multiple HPV type infections. To address this issue, variables were created based on
overall behavior pattern instead of based on intervening time interval.
a- Adjusted for race and lifetime male sexual partners.
b- Adjusted for race.
c- Adjusted for country.
d- Adjusted for country and circumcision status.
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MANUSCRIPT THREE

Introduction:
Few studies have reported the natural history of anal HPV infections among men (173175). Prevalence of anal HPV was observed to be 47.2 % among men who have sex with men
(MSM) and 12.2% among men who have sex with women (MSW) for at least one of 37 HPV
types evaluated (174). Presence of anal HPV among exclusive MSW was an interesting finding
which raised questions as to how infection at this anatomic site occurs. One of the proposed
mechanisms is auto-inoculation whereby genital HPV infection is transferred by the heterosexual
men to the anal epithelium.
Only few studies have evaluated concurrent and sequential cervical and anal HPV
infections among women (176-181). Results of these studies suggested high risk (relative risk as
high as 14.2) of anal HPV infection among women with previous cervical HPV infections of
high risk HPV types (177). Acquisition of anal HPV infections among women was also
associated with having anal sex (177, 178, 181), which is not a likely explanation for
heterosexual men. Furthermore, receiving anal sex did not entirely explain the high rate of
sequential cervical to anal HPV infection among women. Thus, auto-inoculation of previous
cervical infection may also lead to subsequent anal HPV infection observed among women.
To date studies examining sequential genital-anal infections have not been conducted
among men. In the current study, we assessed type-specific (genotype concordant) sequential
acquisition of anal HPV infection following a genital HPV infection for nine vaccine HPV types
84

(HPV 6, 11, 16, 18, 31, 33, 45 52 and 58) among MSW participants of the HIM study cohort. We
also investigated factors associated with incident anal infections following a type-specific genital
HPV infection.
Methods:
Study population
The HIM study recruited participants from Tampa, Florida (U.S.), São Paulo (Brazil), and
Cuernavaca (Mexico) from 2005-2009. Study methodology and recruitment of participants has
been described in detail previously (182, 183). In brief, 4,123 healthy men from three study sites
were followed every six months for a median follow-up time of four years. Eligibility criteria for
the participants were : a) 18–70 years of age; b) residents of one of the study sites; c) no previous
diagnosis of penile or anal cancers; d) no previous diagnosis of genital warts; e) no symptoms of
a sexually transmitted infection (STI) and not receiving treatment for an STI; f) not participating
in an HPV vaccine study; g) no history of HIV or AIDS; h) no history of imprisonment,
homelessness, or drug treatment during the past six months; and i) willingness to comply with 10
scheduled visits every six months for four years with no plans to relocate during that time. From
these study participants, consent was obtained for collection of anal canal exfoliated cell
samples. Computer-assisted self-interviewing (CASI) was used to administer questionnaires to
obtain extensive sexual history and demographic characteristics. Signed informed consent was
obtained from all eligible participants, and approval was obtained from the human subjects
committees of the University of South Florida (Tampa, FL), Ludwig Institute for Cancer
Research (São Paulo, Brazil), Centro de Referencia e Treinamento em Doencas Sexualmente
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Transmissíveis e AIDS (São Paulo, Brazil), and Instituto Nacional de Salud Publica de Mexico
(Cuernavaca, Mexico).
External genital and anal HPV DNA samples
Genital cell samples from the coronal sulcus/glans penis, penile shaft, and scrotum were
collected with three prewetted Dacron swabs, which were later combined to form a single genital
sample (182, 183). After collection of genital specimens, 360° of the anal epithelium was
swabbed between the anal os and the anal canal dentate line using a separate swab, among
participants who provided consent for anal specimen collection (173-175). These swabs were
placed in specimen transport medium and stored at -80°C until analyses. Genital and anal HPV
DNA was extracted from these samples by the QIAamp DNA Blood Mini Kit (QIAGEN). For
both genital and anal samples, PCR and HPV genotyping were performed using the Roche
Linear Array assay to detect 37 HPV genotypes (184). Human β-globin was tested to assess
specimen adequacy, with an overall β-globin positivity of 98%.
Statistical analysis
All HPV types in the 9-valent vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58) were
assessed for sequential type-specific genital-anal infections. From the HIM study cohort, 81% of
the men who have sex with women (MSW) consented for collection of anal canal specimens at
baseline and the first follow-up visit (173). Participants with both genital and anal HPV DNA
samples at baseline and at least one follow-up visit were included in this analysis. Men who have
sex with men (MSM), men who have sex with men and women (MSWM), and subjects with anal
HPV DNA-positive results at baseline were excluded from the genital-anal sequential analyses.
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Eligible subjects were assessed for incident anal HPV infection throughout the follow-up
period at each 6 month clinical visit. Subjects with an incident anal HPV infection were
categorized into four groups for evaluation of type-specific sequential genital to anal HPV
infections (Figure 4.1). These groups were: a) Subjects with genital HPV-positive results at the
anal HPV-positive visit and genital HPV-negative results in previous visits; b) Subjects with
genital HPV-negative results at the anal HPV-positive visit and genital HPV-negative results in
previous visits; c) Subjects with genital HPV-negative results at the anal HPV-positive visit and
genital HPV-positive results in previous visits; d) Subjects with genital HPV-positive results at
the anal HPV-positive visit and with genital HPV-positive results in previous visits. Subjects in
group a) had concurrent genital and anal infections and were not included in type-specific
sequential analyses. Subjects without an incident anal HPV infection were also categorized based
on prior genital HPV infection status constituting the at risk population for incidence rate
calculations. Characteristics of participants who were susceptible for an incident anal HPV
infection were compared across prior genital HPV infection status using Chi-square tests and
Monte Carlo estimation of exact p-values.
Anal HPV infection incidence rates and 95% confidence intervals (CI) were calculated
among men with a prior genital HPV infection and among men with no prior genital HPV
infection. Incidence rate ratios (IRR) were calculated for each of the nine HPV types comparing
prior genital and no prior genital infection groups. Grouped analyses were also carried out for
any of the nine types, low risk HPV types (HPV 6, 11) and high risk HPV types (HPV 16, 18,
31, 33, 45, 52, and 58). Separate analyses were conducted to assess incidence rates of concurrent
genital and anal HPV infections (excluded from the sequential analyses). We also examined
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whether a prior anal infection is associated with incidence of a subsequent genital HPV infection
by calculating IRR and 95% CI.
Risk of sequential detection of anal HPV infections following type-specific genital
infections was assessed using a Cox proportional hazards model by estimating crude and
adjusted hazard ratios (HR). Bivariate analyses (adjusting for one co-variable at a time) were
carried out in HPV individual type analyses. Demographic variables and time varying covariates
(alcohol use, smoking, sexual behavior variables) were evaluated in adjusted models. Sample
size was too small to allow for adjustment of multiple covariates at the same time. Grouped
analyses for any of the nine types, low-risk types and high-risk HPV types were carried out to
increase the statistical power to assess risk of sequential genital-anal infections. Demographic
and sexual behavior variables were evaluated in both backward and forward stepwise models for
grouped HPV analyses. Final models included variables using the best-fit approach based on the
lowest Akaike information criterion (AIC) values.
Results:
From the original HIM study cohort of 4,123 men, anal and genital HPV DNA specimens
for baseline and at least one follow-up visit were available for 2,285 men. Men with prevalent
anal HPV infections (n=175) and those who reported either anal or oral sex with a man at any
time through the study follow-up (n=762) were excluded from the analyses. Subjects excluded
from the analyses were younger, had a lower education level, and were more likely to be
MSM/MSWM compared to subjects included in the current analyses. After these exclusions,
1,348 MSW were eligible for inclusion in the current study. A total of 40 incident anal HPV
infections were detected during the follow-up period, with 85% of the incident anal infections
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detected during the first follow-up visit. The median follow-up time in this sub-cohort was 6.8
months (mean 8.4 months, Inter quartile range: IQR 6.5-7.4).
At baseline, 660 men had no prior genital HPV infection and 688 men had a prior genital
HPV infection with any of the nine HPV types evaluated (Table 4.1). These two groups differed
significantly by country, with men from Brazil constituting the highest proportion (64.6%) of
men with a prior genital HPV infection. The two groups also differed by race, with AfricanAmericans (61.9%) constituting the highest proportion of men with a prior genital infection. In
addition, men with prior genital HPV infection reported higher (>2 drinks/day) alcohol use
(p=0.001), greater number of lifetime female sexual partners (10-49 partners, p <0.001), and
greater number of new female sexual partners in the previous 6 months (≥2 partners, p=0.001).
In individual HPV type analyses, men with HPV 16 genital infections had more than a 4fold increased risk of acquiring a subsequent anal HPV 16 infection (Incident rate ratio- IRR=
4.49, 95% CI 1.14, 18.59) [Table 4.2]. Similarly, risk of acquisition of anal HPV infection was
significantly higher for HPV 52 (IRR=15.46, 95% CI 2.53, 162.33) and HPV 58 (IRR=22.89,
95% CI 3.28, 253.09) among men with a prior same type infection at the genitals. In grouped
analyses, men with prior high risk genital HPV infections had more than a 2-fold increased risk
of detection of a subsequent anal HPV infection compared to men with no prior genital
infections ( IRR = 2.61, 95% CI 1.20-6.00, Table 4.2). Overall, men with prior genital HPV
infections had higher incidence rates of subsequent anal HPV infections. Incident rates for
concurrent genital and anal HPV infection were low for HPV 18 (IR= 0.18, 95% CI 0.05-0.73)
and HPV 45 (IR= 0.18, 95% CI 0.4-0.72), and no concurrent infections were observed for other
HPV types. In contrast, prior anal infections were not associated with risk of subsequent genital
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infections (IRR 1.18; 95% CI, 0.64-2.01 for high risk type HPVs and IRR 0.72; 95% CI, 0.092.65 for HPV 16).
In Cox proportional hazard analyses, statistically significant HRs for anal HPV infection
after a genital infection were observed for HPV 16 (HR=4.63, 95% CI 1.41-15.23), HPV 52
(HR=15.78, 95% CI 3.04-81.92) and HPV 58 (HR=19.60, 95% CI 3.56-107.79) [Table 4.3].
These HRs remained statistically significant even after adjusting for demographic and time
varying covariates one at a time (Table 4.3 and Appendix Table 4.1, 4.1b). Similar to the IRR
analyses, a higher but non-significant HR was observed for HPV 6 (HR=4.6, 95% CI 0.93-22.84)
for detection of anal HPV infection after a genital infection. In grouped HPV analyses,
significantly higher adjusted hazard ratios (aHR) were observed for infection with any of the
nine HPV types (aHR= 2.8, 95% CI1.32-5.99), low risk HPV types (aHR=5.89, 95% CI1.29,
27.01), and high risk HPV types (aHR=2.65, 95% CI 1.26, 5.55). Infection with any of the nine
HPV types, low risk HPV types and high risk HPV types were also evaluated by adjusting one
variable at a time with HRs remaining significant after adjustment for demographic and time
varying covariates (Table 4.3 and Appendix Table 4.1a, 4.1b).
Discussion:
This is the first study to report sequential type-specific genital and anal HPV infections
among MSW for the HPV types included in the 9-valent vaccine (HPV 6, 11, 16, 18, 31, 33, 45,
52, and 58). Overall, having a prior genital HPV infection increased the risk of a subsequent anal
infection of the same HPV type, and this association was unaffected by adjusting for sexual
behavior. Men with a prior genital HPV 16 infection had more than a four-fold increased risk of
anal HPV 16 infection compared to men with no prior genital HPV 16 infections. Significantly
higher risk of sequential anal infection after a genital infection were observed in combined
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analyses for high risk HPV types, low risk HPV types, and any of the nine HPV types targeted
by vaccine.
In previous publications, anal HPV infections were detected among MSW with a
prevalence of 12.2% for any HPV type and 2.2% for HPV 16 (174). It is not clear how MSW
acquire these infections. Our study provides the first evidence of auto-inoculation of genital
infections as a possible mechanism. Among women, only two studies have assessed sequential
acquisition of type-specific anal HPV infection from a prior cervical infection. A study in the
Hawaii HPV cohort found a high risk for sequential cervical to anal HPV infection with an aHR
of 17.33 (95% CI 10.22–29.39) for any type and an aHR of 13.25 (95% CI 3.43–51.22) for HPV
types 16 and 18 (176). Another study from the same cohort also found a high risk for sequential
acquisition of anal infections after cervical infection, with a relative risk (RR) of 20.5 (95% CI:
16.3-25.7) for any HPV type and a RR of 14.2 (9.86-20.5) for high risk HPV types (177). Other
studies have also indicated associations between anal and cervical HPV infections, although they
did not conduct sequential analyses. A study found high concurrence rate of anal and cervical
HPV infections with an adjusted odds ratio (aOR) of 3.3 (95% CI, 2.5-4.4) (178). In a study
among women in American Samoa, authors’ found that women with anal HPV infections were
more likely to have a history of prior cervical infections (aOR = 3.32, 95% CI 1.10–10.00) (179).
Another study found that anal HPV infections were associated with cervical HPV infection with
a relative risk (RR) = 1.3 (95% CI, 1.1–1.4) (180). A concordance rate of 20% for anal HPV
infections among women with pre-existing cervical HPV infections was observed in another
study (181).
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In this study, risk of sequential acquisition of anal HPV infections was unaffected by
sexual behavior and other demographic characteristics. Our analyses included exclusively MSW
subjects and excluded any subjects who reported either oral or anal sex with men throughout the
follow-up period. As number of female sexual partners and frequency of sexual intercourse with
women did not explain presence of anal HPV infections, a likely explanation of these infections
is auto-inoculation through prior genital infections. Auto-inoculation from genital infections may
occur through contact of the hand, toilet paper, undergarments, towel, or other objects. Digital
contact through female sexual partners is also a possibility, but we did not have information
available to assess such transmission. Absence of other explanatory factors and significantly high
risk of sequential infections observed in our analyses indicate that auto-inoculation is a likely
explanation.
To the best of our knowledge, no other study has assessed the risk of type-specific
sequential genital-anal infections among heterosexual men. Strengths of the current study are
large sample size, multinational nature of the cohort, and standard HPV DNA genotyping
methods (190-194). Apart from these strengths, the following limitations may have affected our
results. Despite these strengths, there are limitations that need to be considered when interpreting
study results. We did not have information regarding HPV infections prior to the study start;
therefore, participants may have had genital HPV infections prior to enrollment that
subsequently cleared. This may have led to misclassification of participants with respect to their
classification of their prior genital infection status. It is also possible that participants acquired
anal HPV infections prior to the study start. These infections may have been latent and later
detected and classified as incident anal infections during the follow-up. Similar to genital HPV
infections, it is possible that anal HPV infections may be retained in a latent state in basal
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epithelial stem cell pool (185-189). However, re-activation of a latent infection is less likely in
immune competent HIM study participants, and the detection of very low viral load of a latent
infection is not possible with current HPV DNA detection methods (186-188). Future studies are
needed to assess the role of latent HPV infections particularly in immune-competent individuals.
Although 2,285 subjects provided anal specimens at baseline, fewer specimens were
available after the fourth visit. Subjects were either lost to follow-up or excluded due to reporting
of anal/oral sex with men during follow-up visits. Therefore, we carried out grouped analyses to
increase power to assess sequential genital-anal infection for any of the nine types, high-risk
types, and low-risk HPV types. Eligible participants may not have reported having male sexual
partners due to social desirability. Use of computer assisted techniques for recording sexual
behavior history should have minimized the effect of such bias. Misclassification of genital and
anal HPV infection status is also possible, especially for infections with low viral load and long
time periods between initial infection and assessment of HPV DNA. Given the robust methods
used for HPV DNA detection in our study, effect of such misclassification should be minimal
(190-194). Furthermore, subjects included in the analyses did not differ from excluded subjects
for sexual behavior variables.
In conclusion, men with prior genital HPV infections are at higher risk of acquiring anal
infections with the same type, with a more than four-fold increased risk for HPV 16. Autoinoculation of genital HPV infection along with other unknown factors may explain the presence
of anal HPV among MSW. Future studies are needed to assess the role of auto-inoculation and
explore other factors associated with high rates of anal HPV infection following a genital
infection among MSW. These findings also suggest that the prevention of genital HPV infection
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through vaccination and other methods may help curtail anal HPV infection among heterosexual
men.
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The HIM study Participants
(N= 4,123)

Anal HPV testing
(N= 2,285)

MSM and
MSWM* subjects

Men with prevalent
anal HPV infections

Eligible subjects: MSW without a
prevalent anal HPV infection

(N= 762)

(N= 175)

(N= 1,348)

Excluded
Men with no prior genital HPV infection**

Men with prior genital HPV infections**

(N= 660)

(N= 688)

a)
Concurrent
acquisition
(excluded from
sequential
analysis)

Genital HPV (-) in
previous visits and
Genital HPV (+) at
Anal HPV (+) visita

c)

b)
Genital HPV (-) in
previous visits and
Genital HPV (-) at
Anal HPV (+) visitb

Genital HPV (+) in
previous visits and
Genital HPV (-) at
Anal HPV (+) visitc

d)
Genital HPV (+) in
previous visits and
Genital HPV (+) at
Anal HPV (+) visitd

Figure 4.1: Study population for assessment of sequential genital and anal HPV infections among participants of the HIM
study
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Footnotes: HPV- Human Papillomavirus. Each genital and anal HPV infection assessed is type-specific (genotype concordant). (+) means HPV
DNA positive result and (-) means HPV DNA negative result.
*MSM - men who have sex with men, MSWM - Men who have sex with men and women
** No prior genital and prior genital infection status are based on the sequential acquisition of anal HPV infections as indicated by the sub-boxes
following each of these groups.
a- Genital and anal infections occurred at the same visit, so cannot assess sequential risk. Number of men positive according to each type: HPV 64, HPV 11- 5, HPV 16- 10, HPV 18 – 3, HPV 31- 1, HPV 33- 1, HPV 45- 8, HPV 52- 4, HPV 58- 2
b- Number of men positive according to each type: HPV 6- 3, HPV 11- 0, HPV 16- 5, HPV 18 – 4, HPV 31- 0, HPV 33- 1, HPV 45- 3, HPV 522, HPV 58- 2
c- Number of men positive according to each type: HPV 6- 1, HPV 11- 0, HPV 16- 3, HPV 18 – 0, HPV 31- 1, HPV 33- 0, HPV 45- 0, HPV 522, HPV 58- 2
d- Previous genital HPV positive visit was used for to assess risk of subsequent anal infections. Number of men positive according to each type:
HPV 6- 2, HPV 11- 1, HPV 16- 3, HPV 18 – 0, HPV 31- 0, HPV 33- 0, HPV 45- 0, HPV 52- 3, HPV 58- 2
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Table 4.1: Demographic characteristics of MSW (men who have sex with women) according to prior genital HPV infection
with any of the nine type HPVs (6, 11, 16, 18, 31, 33, 45, 52, and 58), among subjects anal HPV negative at baseline in the HIM
study

Entire
Population

No prior genital
infectiona

Prior genital
infectionb

(N=1,348)

(N=660)

(N=688)

United States

510 (37.8)

265 (52.0)

245 (48.0)

Brazil

325 (24.1)

115 (35.4)

210 (64.6)

Mexico

513 (38.1)

280 (54.6)

233 (45.4)

18-30

641 (47.6)

313 (48.8)

328 (51.2)

31-44

501 (37.2)

242 (48.3)

259 (51.7)

45-73

206 (15.3)

105 (51.0)

101 (49.0)

Single or never married

543 (40.4)

256 (47.1)

287 (52.9)

Married/Cohabitating

670 (49.9)

347 (51.8)

323 (48.2)

Divorced/Separated/Widowed

130 (9.7)

55 (42.3)

75 (57.7)

P-valuec

Country of Residence
<.0001

Age, years
0.8082

Marital Status
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0.0710

Table 4.1 (Continued)

Entire
Population

No prior genital
infectiona

Prior genital
infectionb

(N=1,348)

(N=660)

(N=688)

White

589 (44.1)

273 (46.3)

316 (53.7)

African Americans

160 (12.0)

61 (38.1)

99 (61.9)

Asian/Pacific Islander

33 (2.5)

26 (78.8)

7 (21.2)

Mixed race/Othersd

555 (41.5)

296 (53.3)

259 (46.7)

<= 12

578 (43.0)

285 (49.3)

293 (50.7)

13-15

363 (27.0)

178 (49.0)

185 (51.0)

>= 16

404 (30.0)

196 (48.5)

208 (51.5)

No alcohol

276 (20.9)

144 (52.2)

132 (47.8)

<0.5 drinks/day

484 (36.6)

258 (53.3)

226 (46.7)

0.5-2 drinks/day

347 (26.2)

165 (47.6)

182 (52.4)

> 2 drinks/day

216 (16.3)

83 (38.4)

133 (61.6)

P-valuec

Race
<.0001

Education, years
0.9708

Alcohol use

98

0.0010

Table 4.1 (Continued)

Entire
Population

No prior genital
infectiona

Prior genital
infectionb

(N=1,348)

(N=660)

(N=688)

Never

776 (57.6)

376 (48.5)

400 (51.5)

Former

275 (20.4)

145 (52.7)

130 (47.3)

Current

296 (22.0)

139 (47.0)

157 (53.0)

No

771 (57.2)

377 (48.9)

394 (51.1)

Yes

577 (42.8)

283 (49.0)

294 (51.0)

0-1

114 (8.5)

79 (69.3)

35 (30.7)

2-9

662 (49.1)

358 (54.1)

304 (45.9)

10-49

484 (35.9)

183 (37.8)

301 (62.2)

>= 50

88 (6.5)

40 (45.5)

48 (54.5)

None

843 (65.0)

440 (52.2)

403 (47.8)

1

340 (26.2)

146 (42.9)

194 (57.1)

>= 2

114 (8.8)

44 (38.6)

70 (61.4)

P-valuec

Smoking status
0.3432

Circumcision
1.0000

Lifetime female sexual partners
<.0001

New female sexual partners
in previous 6 months
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0.0011

Footnotes:
Abbreviation: HPV, human papillomavirus; MSW, men who have sex with women.
a - No prior genital infection group includes participants who are susceptible to acquire anal incident infection and do not have prior type
specific genital HPV infection.
b – With prior genital infection group includes participants who are susceptible to acquire anal incident infection and have a prior type
specific genital HPV infection.
c - p-values for categorical variables were calculated using the chi-square test with Monte Carlo estimation of p-values, α = 0.05,
d - Includes mixed race, American Indians, Alaska natives, Native Hawaiians or other races
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Table 4.2: Incidence rate of anal human papillomavirus (HPV) infection, by prior genital HPV infection status among MSW
(men who have sex with women) in the HIM Study
No prior genital HPV infection
HPV
types

Prior genital HPV infection

Subjects
at risk

Incident
infections

Personmonths

660

12

5704.0

Incidence per
1000 personmonths
(95% CI)
2.10 (0.12, 3.70)

1086

3

9542.3

0.31 (0.10, 0.98)

772

11

6695.1

1.64 (0.91, 2.97)

HPV 6

1104

3

9554.1

HPV 11

1299

0

HPV 16

1036

HPV 18

Any
type*
Low risk
types**
High risk
types***

Subjects
at risk

Incident
infections

Personmonth

Incidence per
1000 personmonths
(95% CI)

Incidence
rate ratio
(95% CI)

688

25a

5817.8

4.29 (2.90, 6.36)

2.04 (0.99, 4.46)

262

4

2288.8

1.75 (0.65, 4.66)

5.56 (0.94, 37.95)

576

21a

4895.0

4.30 (2.80, 6.58)

2.61 (1.20, 6.00)

0.31 (0.10, 0.97)

224

3

1967.3

1.52 (0.49, 4.73)

4.86 (0.65, 36.26)

11441.5

0.00 (NE)

47

1

437.7

2.28 (0.32,16.22)

NE

5

9034.6

0.55 (0.23, 1.33)

286

6

2415.7

2.48 (1.11, 5.53)

1249

4

10902.3

0.37 (0.14, 0.98)

95

0

856.2

0.00 (NE)

4.49 (1.14, 18.59)
NE

HPV 31

1259

0

11164.6

0.00 (NE)

84

1

707.2

1.41 (0.20, 1.00)

NE

HPV 33

1325

1

11691.3

0.09 (0.01, 0.61)

21

0

180.6

0.00 (NE)

NE

HPV 45

1261

3

11102

0.27 (0.09, 0.84)

81

0

682.1

0.00 (NE)

NE

HPV 52

1169

2

10142.3

0.20 (0.24, 1.17)

176

5

1640.3

3.05 (1.10, 6.33)

15.46 (2.53, 162.33)

1241

2

10875.8

0.18 (0.08, 0.76)
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4

950.1

4.21 (1.40, 9.95)

22.89 (3.28, 253.09)

HPV 58

Footnotes: Prior genital HPV infection with the same HPV genotype. All the participants were MSWs (men who have sex with women) and never
reported having anal or oral sex with men during the 4 year follow-up time.
*Any type includes infections from any of the nine vaccine type HPVs (6, 11, 16, 18, 31, 33, 45 52 and 58)
** Low risk types include HPV 6 and 11
*** High risk types include HPV 16, 18, 31, 33, 45, 52, and 58
NE=Not estimable. Incidence rate ratio and 95% confidence intervals were calculated using a Poisson model with log link function; Included in the
9-valent HPV vaccine.
a- Combining different HPV types for analyses resulted in higher number of incident anal infections among men with prior genital infection with
any of the nine types and the high risk HPV types.
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Table 4.3: Risk of sequential acquisition of anal human papillomavirus (HPV) infection following a genital
HPV infection among MSW (men who have sex with women) in the HIM Study

HPV types
*

Any type
Low risk

Crude

Adjusted

HR (95% CI)

HR (95% CI)

2.19 (1.10, 4.39)

2.81 (1.32, 5.99)

a
b

5.41 (1.21, 24.16)

5.89 (1.29, 27.01)

2.89 (1.38, 6.02)

2.65 (1.26, 5.55)c

Adjustedd

Adjustede

Adjustedf

Adjustedg

HR (95% CI)

HR (95% CI)

HR (95% CI)

HR (95% CI)

2.28 (1.10, 4.72)

2.53 (1.21, 5.29)

5.14 (1.40, 18.82)

5.14 (1.40, 18.82)

5.16 (1.15, 23.17)

7.80 (1.41, 43.16)

NE

NE

3.34 (1.53, 7.28)

6.95 (1.91, 25.27)

6.95 (1.91, 25.27)

**

types

High risk
***

types

3.13 (1.43, 6.83)

6

4.61 (0.93, 22.84)

NE

4.66 (0.92, 23.56)

6.19 (1.03, 37.25)

NE

5.65 (1.13, 28.24)

11

NE

NE

NE

NE

NE

NE

16

4.63 (1.41, 15.23)

NE

4.46 (1.34, 14.85)

6.44 (1.91, 21.66)

6.50 (1.06, 39.69)

5.22 (1.55, 17.57)

18

NE

NE

NE

NE

NE

NE

31

NE

NE

NE

NE

NE

NE

33

NE

NE

NE

NE

NE

NE

45

NE

NE

NE

NE

NE

NE

52

15.78 (3.04, 81.92)

NE

23.35 (2.57, 211.94)

14.52 (2.77, 76.03)

17.95 (1.33, 242.47)

NE

58

19.60 (3.56, 107.79)

NE

23.50 (4.19, 131.84)

23.56 (3.72, 149.07)

40.54 (4.51, 364.28)

35.70 (5.11, 249.28)

Footnotes:
Reference group consists of men without a prior genital HPV infection of the same genotype
*Any type includes infections from any of the nine vaccine type HPVs (6, 11, 16, 18, 31, 33, 45 52 and 58)
** Low risk types include HPV6 and 11
*** High risk types include HPV 16, 18, 31, 33, 45, 52, and 5
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a- Adjusted for marital status and frequency of sexual intercourse with female partners as a time varying covariate based on
best fit model
b- Adjusted for country based on best fit model
c- Adjusted for marital status based on best fit model
d- Adjusted for alcohol use as a time varying covariate
e- Adjusted for lifetime female sexual partners as a time varying covariate
f- Adjusted for number of new female partners in past 6-12 months as a time varying covariate
g- Adjusted for frequency of sexual intercourse with female partners as a time varying covariate
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CONCLUSION AND RECOMMENDATIONS

HPV infections among men are associated with HPV-related diseases in both men and
women. Early studies of HPV focused on infection among women, and it is just recently that we
have begun to study HPV infection among men. We have learned that men’s response to HPV
infection is different from that of women, making it important to study and understand the
natural history of HPV infection among men. Results discussed here provide important
information in regards to incidence, persistence, and recurrence of anogenital α- mucosal HPV
types 6, 11, 16, 18, 31, 33, 45, 52 and 58.
Results from section 3.3 suggest that men with anti-HPV antibodies largely remain
susceptible to genital HPV infections as these antibodies do not provide protection against
subsequent infections with HPV types 6, 11 and 16. There was an indication of a protective
effect for persistent HPV 18 infections. Various factors associated with measurement/assessment
of serum antibody level can affect anti-HPV antibody levels. With current suboptimal HPV
vaccine coverage among both men and women in U.S., it is essential to promote HPV
vaccination and other preventive measures to target HPV-associated diseases.
Section 4.3 results provide the first description of the recurrence of genital HPV infections
among men. We observed high rates of recurrence for both prevalent (up to 31%) and incident
(up to 20%) HPV infections. Recurrence of genital HPV infections was associated with high risk
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sexual behaviors, such as greater numbers of new sexual partners and lifetime sexual partners.
Analysis of recurrent infections also presents various challenges, including obtaining information
about all prior genital infections, issues associated with differentiating infections from steady
partners and new partners, and the possibility of HPV latency. Future studies are needed to
assess recurrence of HPV infections and explore their role in etiology of HPV-associated
diseases.
Results from section 5.3 are also the first to report sequential acquisition of anal HPV
infection following a type-specific genital infection among MSW. Men with prior genital HPV
16 infections had a more than four-fold increased risk of acquiring subsequent anal HPV 16
infections. Higher hazard ratios were also observed for any of the nine HPV types, high risk
HPV types, and low risk HPV types. In the absence of other explanatory factors, the high risk of
sequential genital-anal infection suggests that auto-inoculation of genital infection is a likely
mechanism for anal HPV acquisition among MSW. Future studies are needed to further explore
this association.
These results provide essential information about the natural history of HPV infection
among men. From a public health perspective, it is important to understand the natural history of
HPV and use this information to control HPV infections and subsequent diseases in both men
and women.
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APPENDIX

Appendix A:Table 2.1- Crude and adjusted hazard ratios (HR) according to sero-status for HPV 6, 11, 16 and 18
infections among men in the HIM study
Incident
infection

Crude HR and
95% CI

Adjusted HR
and 95% CIa

Adjusted HR
and 95% CIb

Adjusted HR
and 95% CIc

Adjusted HR
and 95% CId

Adjusted HR
and 95% CIe

Adjusted HR
and 95% CIf

HPV 6
Sero Sero +

1.00
1.08 (0.74, 1.56)

1.00
1.11 (0.76, 1.62)

1.00
1.05 (0.71, 1.55)

1.00
1.00 (0.63, 1.57)

1.00
1.00 (0.69, 1.46)

1.00
0.95 (0.64, 1.40)

1.00
0.93 (0.62, 1.39)

HPV 11
Sero Sero +

1.00
0.92 (0.55, 1.54)

1.00
0.83 (0.49,1.41)

1.00
0.88 (0.51, 1.51)

1.00
0.78 (0.42, 1.47)

1.00
0.83 (0.49,1.39)

1.00
0.83 (0.49,1.40)

1.00
0.74 (0.43, 1.30)

HPV 16
Sero Sero +

1.00
1.40 (1.08, 1.81)

1.00
1.36(1.05 1.77)

1.00
1.39 (1.07 1.82)

1.00
1.38 (1.03, 1.85)

1.00
1.32 (1.02, 1.71)

1.00
1.34 (1.03, 1.76)

1.00
1.31 (0.997,
1.73)

HPV 18
Sero Sero +

1.00
0.92 (0.59, 1.43)

1.00
0.91 (0.58, 1.43)

1.00
1.01 (0.65, 1.57)

1.00
0.95 (0.57, 1.59)

1.00
0.84 (0.54, 1.31)

1.00
0.80 (0.50, 1.23)

1.00
0.82 (0.52, 1.30)
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Appendix A:Table 2.1 (Continued)
6 month
Crude HR and
Adjusted HR
persistent 95% CI
and 95% CIa
infection

Adjusted HR
and 95% CIb

Adjusted HR
and 95% CIc

Adjusted HR
and 95% CId

Adjusted HR
and 95% CIe

Adjusted HR
and 95% CIf

HPV 6
Sero Sero +

1.00
0.80 (0.37, 1.73)

1.00
0.93 (0.43, 2.00)

1.00
0.93 (0.43, 2.01)

1.00
0.84 (0.34, 2.07)

1.00
0.81 (0.37, 1.75)

1.00
0.87 (0.40, 1.89)

1.00
0.86 (0.39, 1.87)

HPV 11
Sero Sero +

1.00
0.32 (0.08, 1.34)

1.00
0.36 (0.09, 1.48)

1.00
0.17 (0.02, 1.21)

1.00
0.20 (0.03, 1.50)

1.00
0.29 (0.07, 1.20)

1.00
0.32 (0.07, 1.35)

1.00
0.38 (0.09, 1.60)

HPV 16
Sero Sero +

1.00
1.26 (0.79, 2.01)

1.00
1.27(0.79, 2.03)

1.00
1.24 (0.77, 1.99)

1.00
1.35 (0.81, 2.27)

1.00
1.21 (0.75, 1.93)

1.00
1.27 (0.78, 2.06)

1.00
1.24 (0.76, 2.04)

HPV 18
Sero Sero +

1.00
0.22 (0.06, 0.91)

1.00
0.24 (0.06,
0.997)

1.00
0.24 (0.06, 1.01)

1.00
0.17 (0.02, 1.26)

1.00
0.20 (0.05, 0.82)

1.00
0.23 (0.06, 0.93)

1.00
0.22 (0.05, 0.92)

Footnotes: HPV- Human Papillomavirus, HR- Hazard ratios
a - Adjusted for non-sexual behavior covariates
b - Adjusted for lifetime female sexual partners (time varying)
c - Adjusted for new female partners in past 6-12 months (time varying)
d - Adjusted for ever having male oral/anal sexual partners (time varying).
e - Adjusted for lifetime male sexual partners (time varying)
f - Adjusted for new male partners in past 6-12 months (time varying)
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Appendix B: Table 2.2 - Crude and adjusted hazard ratios (HR) stratified by sexual orientation for incident
HPV 6 and 11 infections among HIM Study participants
HPV 6
Number
at risk

Events

Crude HR

Adjusted HR

235
14

1.0
0.86 (0.50, 1.47)

1.0
1.06 (0.58, 1.97 )a

2374
326

75
6

1.0
0.57 (0.25, 1.32)

1.0
0.75 (0.32, 1.75 )b

292
56

40
12

1.0
1.66 (0.87, 3.16)

1.0
1.10 (0.50, 2.46)c

292
96

20
4

1.0
0.62 (0.21, 1.82)

1.0
0.60 (0.20, 1.83)d

MSM
Seronegative
Seropositive

77
22

14
3

1.0
0.81 (0.23, 2.80)

1.0
0.50 (0.11, 2.32)e

77
30

7
3

1.0
1.31 (0.33, 5.26)

1.0
1.99 (0.44, 8.99)e

Six month
persistent
infections
MSW
Seronegative
Seropositive

2345
170

235
14

1.0
1.13 (0.49, 2.60)

1.0
1.41 (0.56, 3.55)f

2374
326

75
6

1.0
0.30 (0.04, 2.20)

1.0
0.35 (0.05, 2.57)g

MSWM
Seronegative
Seropositive

292
56

40
12

1.0
0.47 (0.06, 3.59)

1.0
0.53 (0.07, 4.15)h

292
96

20
4

1.0
NE

1.0
NE

MSM
Seronegative
Seropositive

77
22

14
3

1.0
NE

1.0
NE

77
30

7
3

1.0
1.33 (0.12, 14.72)

1.0
1.16 (0.11, 12.83)i

Incident
infections
MSW
Seronegative
Seropositive

2345
170

MSWM
Seronegative
Seropositive

Events

HPV 11
Number
at risk

Crude HR

Adjusted HR

Footnotes:
HPV- Human Papillomavirus, HR- Hazard ratios, MSW- Men who have sex with women, MSWM- Men who have sex
with women and men, MSM- Men who have sex with men
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a- Adjusted for marital status, alcohol use, lifetime female partners (time varying) and new female partners in past 6-12
months(time varying)
b-Adjusted for country, marital status, and new female partners in past 6-12 months(time varying)
c- Adjusted for race, new female partners in past 6-12 months(time varying) and new male partners in past 6-12
months(time varying)
d- Adjusted for marital status, lifetime female partners (time varying) and new male partners in past 6-12 months(time
varying)
e - Adjusted for new male partners in past 6-12 months(time varying)

f- Adjusted for alcohol use, new female partners in past 6-12 months (time varying) and frequency of sexual
intercourse with female partners in past 6-12 months.
g-Adjusted for smoking, and new female partners in past 6-12 months(time varying)
h- Adjusted for country, i- Adjusted for age
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Appendix C: Table 2.3 – Incident rate ratios comparing high (top 33.3%) seropositive to seronegative and low
seropositive (lower 66.7%) to seronegative individuals for incident and six month persistent infection for HPV6,
11, 16 and 18.
High seropositive (Top 33.3%)
No. At
Person- Incidence rate
risk
years
per 100 personyears
Incident infections
12
89
291.8
4.11
HPV 6
6
176
628.7
0.95
HPV 11
22
137
450.8
4.88
HPV 16
7
126
439.6
1.59
HPV 18
6-Month persistent infections
2
89
297.7
0.67
HPV 6
0
176
634.4
0.00
HPV 11
5
137
460.2
1.09
HPV 16
1
126
442.2
0.23
HPV 18
Low seropositive (Lower 66.7%)
No. At
Person- Incidence rate
risk
years
per 100 personyears
Incident infections
HPV 6
18
194
663.75
2.71
HPV 11
11
337
1260.1
0.87
HPV 16
48
283
964.8
4.98
HPV 18
15
265
962.6
1.56
6-Month persistent infections
HPV 6
5
194
669.1
0.75
HPV 11
2
337
1265.6
0.16
HPV 16
16
283
981.1
1.63
HPV 18
1
265
968.7
0.10

Seronegative
No. At
Personrisk years

Incidence
rate per 100
person-years

Incidence rate
ratio and 95% CI

10898.7
11404.3
10177.2
11578.6

2.93
0.97
3.56
1.73

1.41 (0.72, 2.49)
0.98 (0.35, 2.20)
1.37 (0.85, 2.11)
0.92 (0.37, 1.93)

100 3105 11025.7
37 3132
11451
120 2912 10310.2
74 3202 11642.9
Seronegative
No. At
Personrisk years

0.91
0.32
1.16
0.64

0.74 (0.09, 2.75)
0.00 (NE)
0.93 (0.30, 2.24)
0.36 (0.01, 2.05)

Incidence
rate per 100
person-years

Incidence rate
ratio and 95% CI

319
111
362
200

3105
3132
2912
3202

319
111
362
200

3105
3132
2912
3202

10898.7
11404.3
10177.2
11578.6

2.93
0.97
3.56
1.73

0.93 (0.54, 1.49)
0.90 (0.44, 1.67)
1.40 (1.01, 1.89)
0.90 (0.49, 1.52)

100
37
120
74

3105
3132
2912
3202

11025.7
11451
10310.2
11642.9

0.91
0.32
1.16
0.64

0.82 (0.26, 1.99)
0.49 (0.06, 1.90)
1.40 (0.78, 2.37)
0.16 (0.004, 0.93)
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Footnotes: HPV- Human Papillomavirus
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Appendix D: Table 4.1a: Risk of sequential acquisition of anal human papillomavirus (HPV) infection following a
genital HPV infection
Country

Age

Marital status

Race

Crude

Adjusteda

Adjustedb

Adjustedc

Adjustedd

HR (95% CI)

HR (95% CI)

HR (95% CI)

HR (95% CI)

HR (95% CI)

2.19 (1.10, 4.39)

2.20 (1.09, 4.45)

2.25 (1.13, 4.51)

2.01 (1.00, 4.05)

2.24 (1.11, 4.50)

5.41 (1.21, 24.16)

5.90 (1.29, 27.01)

5.10 (1.14, 22.83)

5.79 (1.29, 25.95)

5.56 (1.24, 25.05)

2.89 (1.38, 6.02)

3.07 (1.46, 6.47)

2.94 (1.40, 6.15)

2.65 (1.26, 5.55)

3.00 (1.42, 6.32)

6

4.61 (0.93, 22.84)

5.23 (1.03, 26.59)

4.41 (0.89, 21.93)

4.66 (0.93, 23.22)

4.69 (0.94, 23.36)

11

NE

NE

NE

NE

NE

16

4.63 (1.41, 15.23)

6.07 (1.82, 20.19)

4.66 (1.41, 15.35)

4.53 (1.36, 15.04)

5.61 (1.67, 18.87)

18

NE

NE

NE

NE

NE

31

NE

NE

NE

NE

NE

33

NE

NE

NE

NE

NE

45

NE

NE

NE

NE

NE

52

15.78 (3.04, 81.92)

15.20 (2.88, 80.20)

18.11 (3.36, 97.11)

15.03 (2.88, 78.30)

17.93 (3.44, 93.43)

58

19.60 (3.56, 107.79)

25.12 (4.17, 151.46)

20.01 (3.63, 110.89)

20.49 (3.69, 113.70)

24.84 (3.70, 166.78)

HPV types
Any type

*

Low risk types

**

High risk types**

Footnotes:
Reference group consists of men without a prior genital HPV infection of the same genotype
*Any type includes infections from any of the nine vaccine type HPVs (6, 11, 16, 18, 31, 33, 45 52 and 58)
** Low risk types include HPV6 and 11
*** High risk types include HPV 16, 18, 31, 33, 45, 52, and 5
a

Adjusted for country

b

Adjusted for age

c

Adjusted for marital status
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d
e

Adjusted for Race

Adjusted for smoking status as a time varying covariate

f

Adjusted for alcohol use as a time varying covariate

g

Adjusted for lifetime female sexual partners as a time varying covariate

h

Adjusted for number of new female partners in past 6-12 months as a time varying covariate

i

Adjusted for frequency of sexual intercourse with female partners as a time varying covariate
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Appendix E: Table 4.1b: Risk of sequential acquisition of anal human papillomavirus (HPV) infection following a
genital HPV infection
Smoking

Alcohol

status

use

Adjusted
HPV types

a

Adjusted

Lifetime female

New female partners

intercourse

partners
b

Adjusted

Frequency of

c

Adjusted

d

Adjustede

HR (95% CI)

HR (95% CI)

HR (95% CI)

HR (95% CI)

HR (95% CI)

2.14 (1.07, 4.29)

2.28 (1.10, 4.72)

2.53 (1.21, 5.29)

5.14 (1.40, 18.82)

5.14 (1.40, 18.82)

5.74 (1.28, 25.74)

5.16 (1.15, 23.17)

7.80 (1.41, 43.16)

NE

NE

2.83 (1.35, 5.91)

3.13 (1.43, 6.83)

3.34 (1.53, 7.28)

6.95 (1.91, 25.27)

6.95 (1.91, 25.27)

6

4.84 (0.97, 24.14)

4.66 (0.92, 23.56)

6.19 (1.03, 37.25)

NE

5.65 (1.13, 28.24)

11

NE

NE

NE

NE

NE

16

4.21 (1.27, 13.99)

4.46 (1.34, 14.85)

6.44 (1.91, 21.66)

6.50 (1.06, 39.69)

5.22 (1.55, 17.57)

18

NE

NE

NE

NE

NE

31

NE

NE

NE

NE

NE

33

NE

NE

NE

NE

NE

45

NE

NE

NE

NE

NE

52

15.49 (2.97, 80.79)

23.35 (2.57, 211.94)

14.52 (2.77, 76.03)

17.95 (1.33, 242.47)

NE

58

25.39 (4.13, 156.24)

23.50 (4.19, 131.84)

23.56 (3.72, 149.07)

40.54 (4.51, 364.28)

35.70 (5.11, 249.28)

All types

*

Low risk types

**

High risk types

***

Footnotes:

Reference group consists of men without a prior genital HPV infection of the same genotype
*Any type includes infections from any of the nine vaccine type HPVs (6, 11, 16, 18, 31, 33, 45 52 and 58)
** Low risk types include HPV6 and 11
*** High risk types include HPV 16, 18, 31, 33, 45, 52, and 5
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aAdjusted for smoking status as a time varying covariate
bAdjusted for alcohol use as a time varying covariate
cAdjusted for lifetime female sexual partners as a time varying covariate
dAdjusted for number of new female partners in past 6-12 months as a time varying covariate
eAdjusted for frequency of sexual intercourse with female partners as a time varying covariate
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Appendix F: Institutional Review Board (IRB) approval
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Appendix G: Institutional Biosafety Committee (IBC) approval
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Appendix H: Informed consent document:
Subject’s Name MCC# 13930
Medical Record # IRB# 102660
Informed Consent to Participate in Research and Authorization to Collect, Use and Share
Your Health Information Moffitt Cancer Center/University of South Florida Information to
Consider Before Taking Part in this Research Study
Researchers at Moffitt Cancer Center (MCC) study many topics. To do this, we need the help of
people who agree to take part in a research study. Research studies include only people who
choose to take part. This document is called an informed consent form. Please read this
information carefully and take your time making your decision. Ask the researcher or study staff
to discuss this consent form with you. Please ask him/her to explain any words or information
you do not clearly understand. We encourage you to talk with your family and friends before you
decide to take part in this research study. The nature of the study, risks, inconveniences,
discomforts, and other important information about the study are listed below.
We are asking you to take part in a research study called: Natural History of HPV Infection in
Men: The HIM Study
The person who is in charge of this research study is Anna Giuliano, PhD. This person is called
the Principal Investigator. However, other research staff may be involved and can act on behalf
of the person in charge.
The research will be conducted at:
H. Lee Moffitt Cancer Center & Research Institute, Inc.
(Moffitt Cancer Center)
12902 Magnolia Drive
Tampa, FL 33612
This research is being sponsored by the National Institutes of Health.
Why is this research being done?
The purpose of this study is to learn about the natural history of Human Papillomavirus (HPV)
infection in men. The study will also find out what factors are linked to HPV in men including
other sexually transmitted diseases (STDs). If you test positive for syphilis, gonorrhea or
chlamydia, we are required by law to report the results to the Florida Department of Health. You
will be able to get free medical treatment from the Florida Department of Health for these STDs.
You will be given a written report of the results of the STD testing.
HPV is a virus that is transmitted through sexual intercourse. This virus is common in men and
women. Some types of this virus can cause warts. Other types of this virus cause changes in the
cervix or cancer in women. Anal, penile and oropharyngeal (cancer that develops in the part of
the throat just behind the mouth, called the oropharynx) cancers are very rare cancers associated
with HPV infections.
Most people with this virus have no signs of infection. There is no effective treatment against the
virus yet. In most cases the infection goes away on its own. Little is known about this virus in
men. Through this study, the researchers hope to learn more about HPV infection in men, so that
they can develop effective programs to reduce HPV disease burden in men and
[Original Approval Date: 08/12/2004] Version 24 Revision Date 06/24/2013
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women.
The use of condoms may help lessen the chances of spreading HPV and other STDs between
sexual partners. However if the HPV infection is on skin not covered by the condom, it is
possible for the disease to spread.
Why are you being asked to take part?
We are asking you to take part in this study because you are a man between 18 and 70 years of
age, live in southern Florida, US; Sao Paulo, Brazil; or the state of Morelos, Mexico. A pilot
study will be completed consisting of 180 men (about 50 men per year for 3½ years) ages 45 to
70 who live in southern Florida. You have never been told you have penile or anal cancer or
genital warts and you are willing to attend scheduled visits every six months in the next 4 years.
We want to learn about the natural history of Human Papillomavirus (HPV) infection in men,
including what factors are linked to HPV in men.
How long will you be asked to stay in the study?
This study may take up to 5 years to complete; however, you will only be active in this study for
approximately 4 years. In order for the researchers to learn about the natural history of HPV, the
study will need to last for 4 years.
How often will you need to come for study visits?
A study visit is one you have with the study doctor or study staff. This visit is different than
visits with your regular doctor. You will need to come for an additional 9 study visits, once every
6 months for 4 years. Most study visits will take about 45 minutes. Some may be shorter.
At each visit, the doctor or staff will:
• Do an exam of the skin on your genitals. The health provider will swab the outside of your
penis and the anal canal with a wet swab to test for HPV. If visible lesions or warts are present,
samples will be collected from those areas using a wet swab. You will be told if the health
provider finds any sores or lesions that need care.
• Collect an oral cell sample using mouthwash. You will be asked to swish your mouth with
mouthwash (this is called an oral rinse). The unused oral sample will be frozen and stored at the
Moffitt Cancer Center in Tampa, FL. You will be asked at the end of this consent if you agree to
have these samples stored for future testing by the investigators.
• Collect a blood sample. The clinic staff will use a needle to draw 2-3 tablespoons of blood from
a vein in your arm. The blood will be tested for HPV antibodies (proteins produced by the body
as part of its defense against HPV). Once a year, a portion of this blood will also be tested for
HSV 2 (herpes simplex virus 2). The blood sample collected at your last visit will not be tested
for HSV2. The blood collected at your second visit will also be tested for syphilis. HSV 2 and
syphilis are two sexually transmitted infections. The unused blood will be frozen and stored at
the Moffitt Cancer Center in Tampa, FL. You will be asked at the end of this consent if you
agree to have
[Original Approval Date: 08/12/2004] Version 24 Revision Date 06/24/2013
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these samples stored for future testing by the investigators. Once a year, you will be asked for a
urine sample. This urine sample will be tested for chlamydia. You will not provide urine at your
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last visit. The urine sample collected at your second visit will also be tested for gonorrhea.
Chlamydia and gonorrhea are two sexually transmitted infections.
• Give you a survey to complete. Because HPV is passed on by skin-to-skin contact, such as
during sex, you will be asked questions on the survey about your sexual history. For example
you may be asked about the number of sex partners you have had, and the date of the last sex.
Some of these questions may be personal or sensitive. You can refuse to answer any question.
• Complete a Symptom and Medication Review checklist.
A schedule and sequence of clinic procedures and laboratory specimen collection is attached to
this consent form.
How many other people will take part?
About 1000 men, ages 18-44, will take part in this study in the Tampa Bay area. People will also
take part at other study sites. A total of about 3000 men will take part. About fifty (50) men per
year for the next 3½ years, for a total of 180 men ages 45 – 70, will be added as a pilot study.
Will the treatment you get change if you take part in this study?
The treatment you now get from your regular doctor will not change if you take part in this
study. You are free to withdraw from the study at any time without causing bad feelings or
changing you medical care.
What other choices do you have if you decide not to take part?
If you decide not to take part in this study, that is okay. This choice will not affect your usual
health care. There is no cure for HPV infection in men; however there are options for treating
visible warts, however new warts may appear during treatment. Treatment options include;
application of therapeutic agents such as bichlor- or trichloracetic acid, podophyllum, or
imiquimod, cryotherapy (freezing), laser therapy, or excision (surgical removal).
How do you get started?
If you decide to take part in this study, you will need to sign this consent form. Because the study
needs to enroll men who can return for 9 more visits, study staff will ask for your complete
contact information. This is needed in order to send reminders about your appointments.
At the end of the visit the study staff will schedule your next clinic visit. You will be given
instructions for the next visit: no sex 24 hours before the visit, no washing of genitals with soap
the morning of the visit. All these steps are necessary to allow for detection of HPV.
The study staff will contact you to remind you of the next appointment by sending a reminder
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letter two weeks prior to the appointment or an e-mail one week before the appointment,
whichever is your choice of contact. In addition, the study staff will contact you the day prior to
the appointment date. If you wish to withdraw from the study, you should tell the staff so they
will not continue to contact you.
What will happen during this study?
At each visit, the health provider will do an exam of the skin on your genitals. The provider will
swab the outside of your penis with a wet swab to test for HPV. If visible lesions or warts are
present, samples will be collected from those areas using a wet swab. You will be told if the
health provider finds any sores or lesions that need care. If during visual physical examination,
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genital warts are detected, the clinician can refer you to an outside clinic for treatment and follow
up. Prescription may be written for topical cream. If we discover lesions that look like they may
be the kind of lesions that could turn into cancer, we will refer you for an evaluation at Moffitt
Cancer Center. This evaluation will be free.
You will be asked to give an oral cell sample using mouthwash at each visit. A subset of the
study participants (200 men) will also be asked to provide 2 oral samples on the same day for
one visit only. You will also be asked to give a blood sample at each visit. The clinic staff will
use a clean needle to draw 2-3 tablespoons of blood from a vein in your arm. The blood will be
tested for HPV antibodies. Once a year, a portion of this blood will also be tested for HSV 2
(herpes simplex virus 2). The blood collected at your second visit will also be tested for syphilis.
Once a year, you will be asked to give a urine sample that will be tested for chlamydia. The urine
sample collected at your second visit will also be tested for gonorrhea.
If you have a biopsy of an external genital wart/lesion, you will be asked to give a blood sample
during the biopsy visit. The clinic staff will use a clean needle to draw about 1 tablespoon of
blood from a vein in your arm. The blood will be used for ADCC (antibody-dependent cellular
cytotoxicity) testing. ADCC testing is a new test to test for HPV antibodies (proteins produced
by the body as part of its defense against HPV). Even if you are not having a biopsy, we might
ask you to donate 1 tablespoon of blood for ADCC testing so that we can compare the blood
samples.
You will be given a questionnaire to complete at each visit. Because HPV is passed on by skinto-skin contact, such as during sex, you will be asked questions on the survey about your sexual
history. For example you may be asked about the number of sex partners you have had, and the
date you last had sex. Some of these questions may be personal or sensitive. You can refuse to
answer any question.
In addition to the questionnaire above, you will be asked to complete a medical history
questionnaire, a physical activity questionnaire, a food frequency questionnaire, and a symptom
and medication review checklist during your clinic visits. A schedule and sequence of clinic
procedures, questionnaires and laboratory specimen collection is attached to this consent form.
Results of HPV testing
The test for human papillomavirus (HPV) being used in this study is a research test and will
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include the 37 HPV types most commonly found in the genital area.
• There is no FDA licensed test for HPV detection in men.
• You will receive your results in approximately 6 months.
• You will receive the HPV results from the study clinician, starting at visit 3. The clinician does
not have access to the specific HPV type, but you will be told if you are positive or negative for
any of the 37 types.
• You will not receive the results from the oral cell sample collection.
Will you be paid for taking part in this study?
We will pay you for the time you volunteer in this study.
• You will get a total of $540 to be part of this study. You will get paid for each completed visit.
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• The payment will be as follows: Baseline Visit (Visit 1): $50, Visit 2: $75, Visit: 3: $40, Visit
4: $40, Visit 5: $50, Visit 6: $75, Visit 7: $40, Visit 8: $50, Visit 9: $40, Visit 10: $80.
Will it cost anything to be in this study?
It will not cost you anything to take part in the study.
You will not have to pay for study tests or procedures in this study.
Your insurance plan will not have to pay for any study costs.
What are the potential benefits if you take part in this study?
We don’t know if you will get any health benefits by taking part in this study. There may be a
benefit to researchers who need to know the natural history of HPV in men to develop methods
to prevent infection and to slow or halt its progress to disease. Future studies may help
researchers know how HPV is passed on and how long men have the infection. In addition to
HPV testing you will also be tested for chlamydia, syphilis, herpes simplex virus 2 and
gonorrhea free of charge.
What are the risks if you take part in this study?
The questions you are asked are personal and sensitive and may cause you to feel shame or
worry. You can refuse to answer any questions. You can refuse to be part of the study at any
time.
When blood is drawn, you may feel some pain and you may faint or feel faint. After blood is
collected, you may have a bruise or pain and a slight risk of infection at the site where the blood
was taken. Rubbing the penis with a wet swab, and giving a urine sample will not cause you
pain, but it may cause some shame or social discomfort. There are no risks to giving an oral cell
sample. [Original Approval Date: 08/12/2004] Version 24 Revision Date 06/24/2013
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Many people have HPV. Most infections clear on their own. You will not need to make changes
in your health care or the health care of your partner. The use of condoms may help lessen the
chances of HPV spreading between sexual partners. However if the HPV infection is on skin not
covered by the condom, it is possible for the disease to spread. Your female partner(s) should
have regular Pap smears regardless of your HPV status.
Risks of undetected HPV in female partners
Some types of the HPV virus that can be transmitted between sexual partners cause changes in
the cervix in women. To detect these changes in the cervix, your female partner should get a
yearly pap smear. We advise you to talk to your female partner about getting a yearly pap smear
no matter what your HPV test results are.
Moffitt Cancer Center Injury Statement
If you believe you have been injured as a result of your participation in this study or if you have
questions about your rights as a person who is taking part in a research study, you may call the
Moffitt Cancer Center Risk Manager at 813-745-4219. Florida law (Statute 768.28) limits the
liability of Moffitt Cancer Center. Moffitt Cancer Center cannot pay for lost wages, disability, or
discomfort. A copy of this statute is available upon request at 813-745-1869. This statute
provides that damages are available only to the extent that negligent conduct of a Moffitt Cancer
Center employee caused your injuries. The damages available in this situation are limited by law.
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The Moffitt Cancer Center and investigators have made no provision for monetary compensation
in the event of physical illness or injury resulting from this study.
Be aware that your health care payer/insurer might not cover the costs of study-related injuries or
illnesses.
The use and disclosure of your personal health information
We understand that information about you and your health is personal, and we are committed to
protecting the privacy of that information. Because of this commitment, we must obtain your
written authorization before we use or disclose your information for this study.
Research at the Moffitt Cancer Center may be undertaken jointly with the University of South
Florida or other persons or entities under an organized health care arrangement. By signing this
form you are permitting researchers at Moffitt Cancer Center to use personal health information
for research purposes within its organized health care arrangements. You are also allowing the
Moffitt Cancer Center to disclose your personal health information to outside organizations or
individuals that participate in this study. We may publish what we find out from this study. If we
do, we will not let anyone know your name. We will not publish anything that would let people
know who you are.
If you do not agree to the use and disclosure described above, you cannot be in the study.
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Who will disclose, receive, and/or use your information?
Federal law says we must keep your study records private. We will keep the records of this study
private by keeping them in a locked area or on a secure computer. The survey will be marked
with a code and not your name. If you give your permission to be contacted, the study staff will
not identify the nature of participation. Samples and data sent to the Moffitt Cancer Center and
Johns Hopkins University will only be marked with codes. The study staff will keep the
codebook that links your name to the code number in a locked file. The consent forms, test
results and survey will be kept in locked areas. To do this research, the following people and/or
organization(s) will be allowed to disclose, use, and receive your information, but they may only
use and disclose the information to the other parties on this list, to you or your personal
representative, or as permitted by law:
• Every research site for this study, including the Moffitt Cancer Center, and each site’s study
team, research staff and medical staff;
• Any person who provides services or oversight responsibilities in connection with this study;
• Every member of the Moffitt Cancer Center workforce who provides services in connection
with this study;
• The person who is responsible for the study nationwide or worldwide (study chairperson);
• Any laboratories and other individuals and organizations that use your health information in
connection with this study;
• Any sponsor of the study, including the following sponsors: National Institutes of Health
• Any federal, state or local governmental agency that regulates the study (such as the FDA,
Florida Department of Health (FDH), the U.S. Department of Health & Human Services
(DHHS), and the Office for Human Research Protections (OHRP));
• Other government agencies in this or other countries;
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• The designated Protocol Review and Monitoring Committees, Institutional Review Boards,
Privacy Boards, Data and Safety Monitoring Board and their related staff that have oversight
responsibilities for this study;
• The National Cancer Institute in evaluating the ongoing research of the Moffitt Cancer Center
as a Comprehensive Cancer Center.
The organizations and people listed above may employ or pay various consultants and
companies to help them understand, analyze and conduct this study. All of these people may not
be known now, but if you would like to have more specific information about this at any time
during the study, you may ask the study doctor and your questions will be answered.
Moffitt Cancer Center cannot guarantee the privacy of your information, or block further use or
distribution, after the information has left the Moffitt Cancer Center. Others listed above may
further disclose your information, and may no longer be covered by federal privacy regulations.
If all information that does or can identify you is removed from your records, the remaining
information will no longer be subject to this authorization and may be used or shared for other
purposes.
You might have the right to see and copy your health records related to this research. You
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might not be able to see or copy some of your records until after all participants finish the study.
If it is necessary for your care, your records will be provided to you or your regular doctor.
What information will be used or disclosed?
By signing below, you authorize the use and disclosure of your entire study record and any
medical or other records held by Moffitt Cancer Center, including, but not limited to, HIV/AIDS,
mental health, substance abuse or genetic information. The purpose for the uses and disclosures
you are authorizing is to conduct the study explained to you during the informed consent and
research authorization process and to ensure that the information relating to that study is
available to all parties who may need it for research purposes.
Your authorization to use your health information will never expire unless and until you
expressly revoke it in writing to the investigator on the first page of this form. If you revoke your
authorization, you will not be able to continue in the study.
By signing this form, you authorize the use and/or disclosure of your protected health
information described above. Your information may also be used as necessary for your researchrelated treatment, to collect payment for your research-related treatment (when applicable), and
to run the business operations of the Moffitt Cancer Center.
Any data collected prior to your letter will continue to be used as necessary to preserve the
integrity of the study, however no additional information will be collected after you withdraw
your authorization.
You will receive a signed copy of this form.
What happens if you decide not to take part in this study?
You should only take part in this study if you want to volunteer. You should not feel that there is
any pressure to take part in the study, to please the investigator or the research staff. You are free
to participate in this research or withdraw at any time. There will be no penalty or loss of
benefits you are entitled to receive if you stop taking part in this study.
What if you join the study and then later decide you want to stop?
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If you decide you want to stop taking part in the study, tell the study staff as soon as you can.
If for some unplanned reason you move from the area during the study, you agree to tell the
study staff as soon as you know you are moving.
It is important to understand that you may leave the study at any time. It is important to let the
study staff know if you will not be able to keep an appointment or leave the study.
New information about the study
During the course of this study, we may find more information that could be important to you.
This includes information that, once learned, might cause you to change your mind about
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being in the study. We will notify you as soon as possible if such information becomes available.
Where can you get the answers to your questions, concerns, or complaints?
If you have any questions, concerns or complaints about this study, or experience an adverse
event or unanticipated problem, call Dr. Anna Giuliano at (813) 745-6820.
If you have questions about your rights as a research patient at Moffitt Cancer Center, call the
Corporate Compliance Department at The Moffitt Cancer Center at (813) 745-1869.
If you have questions about your rights as a participant in this study, general questions, or have
complaints, concerns or issues you want to discuss with someone outside the research, call the
USF IRB at (813) 974-5638.
Consent to Take Part in this Research Study and Authorization to Collect, Use and Share
Your Health Information
It is up to you to decide whether you want to take part in this study. If you want to take part,
please sign the form, if the following statements are true. A representative of the Moffitt Cancer
Center must answer your questions completely before providing this form to you. You or your
personal representative should read this form and understand it before signing below.
I freely give my consent to take part in this study and authorize that my health information
as agreed above, be collected/disclosed in this study. I understand that by signing this form I
am agreeing to take part in research. I have received a signed copy of this form to take with me.
Signature of Person Taking Part in Study Date
Printed Name of Person Taking Part in Study
Statement of Person Obtaining Informed Consent / Research Authorization
I attest that the participant named above had enough time to consider this information, had an
opportunity to ask questions, and voluntarily agreed to be in this study.
Signature of Person Obtaining Informed Consent / Research Authorization Date
Printed Name of Person Obtaining Informed Consent / Research Authorization
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Permission to perform Anal Canal Sampling As part of this study, we would like to test for HPV
that may be in your anal canal. In order to get a sample of cells from your anal canal, the
clinician will use a swab moistened with normal saline (salt water) to swab the anal canal. The
swab will be gently inserted into the anus and turned around while inside the anus.
You do not have to agree to this test to take part in the rest of the study.
Please initial one of the lines below:
____ I agree to anal canal sampling.
____ I DO NOT agree to anal canal sampling.
Permission to store specimens
You are being asked to give permission for your remaining samples to be stored in a specimen
bank for future use at the Moffitt Cancer Center and other collaborating institutions. They will be
stored without any personal information that could link them to you. The samples will have a
code. The study staff will have the codes linking you to the samples stored in a locked, private
area. Samples may be used for evaluation of infectious diseases or immune markers of infection.
The results of this testing would not be available to you or your physician, and would not alter
your care in any manner. If a researcher wishes to use these specimens in a future study, they
would need to submit a research proposal to the University of South Florida Human Subjects
Committee who will act on your behalf to weigh the risks and benefits of future testing of your
specimens, and whether the results can be linked to the coded questionnaire data from this study.
You can choose not to have your specimens stored, and still be part of this study. Also, at any
time you may change your mind and decide that you do not want to have your samples stored. In
that case you must contact Dr. Anna Giuliano at (813) 745-6820 who will ensure that your
samples are destroyed.
Please initial one of the lines below:
____ I agree for my remaining samples to be stored and used for future research studies.
____ I DO NOT agree for my remaining samples to be stored and used for future research
studies.
Permission to be contacted for future studies
You are being asked if you give your permission to be contacted for future studies conducted by
Dr. Giuliano at the Moffitt Cancer Center.
Please initial one of the lines below:
____ I agree to be contacted for future studies.
____ I DO NOT agree to be contacted for future studies.
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